BindingDB logo
myBDB logout

Search by Patent Identification


Patent: (prefix with "US" like US6078908)
PatentDataCompoundsHGNC
(for human-derived proteins)
Patent TitleOrganizationDepositionDownloads
US10336710 12 12 HGNC:17989 Benzimidazole derivatives, preparation method therefor, and applications thereof TBA 05/31/202D 3D TSV
US10336721 35 35 HGNC:7097 Biaryltriazole inhibitors of macrophage migration inhibitory factor Yale University 05/31/202D 3D TSV
US10329302 370 361 HGNC:17967 Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. 05/31/202D 3D TSV
US10329291 53 27 HGNC:934 HGNC:933 C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use TBA 05/31/202D 3D TSV
US10335399 59 59 HGNC:4594 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use TBA 05/31/202D 3D TSV
US10335392 43 41 HGNC:11892 Cyclic compounds useful as modulators of TNF α Bristol-Myers Squibb Company 05/31/202D 3D TSV
US10329286 11 11 FXR (NR1H4) modulating compounds Gilead Sciences, Inc. 05/31/202D 3D TSV
US10329299 436 107 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 05/31/202D 3D TSV
US10329307 74 70 Heterocyclic compounds as inhibitors of platelet aggregation Universite de Montreal 05/31/202D 3D TSV
US10329303 52 52 HGNC:23357 Heterocyclic inhibitors of monocarboxylate transporter The Scripps Research Institute 05/31/202D 3D TSV
US10336717 549 510 HGNC:933 Inhibitors of beta-secretase Vitae Pharmaceuticals, LLC 05/31/202D 3D TSV
US10335409 178 86 Inhibitors of hepatitis C virus Gilead Pharmasset LLC 05/31/202D 3D TSV
US10329320 66 61 Neuroactive steroids, compositions, and uses thereof Sage Therapeutics, Inc. 05/31/202D 3D TSV
US10335401 95 94 HGNC:7045 Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity SHIONOGI & CO., LTD. 05/31/202D 3D TSV
US10336684 60 53 HGNC:19061 Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators Bristol=Myers Squibb Company 05/31/202D 3D TSV
US10329294 290 280 HGNC:17967 Pyrazolopyrimidine inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 05/31/202D 3D TSV
US10329295 163 162 HGNC:17967 Pyrrolotriazine inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 05/31/202D 3D TSV
US10329282 123 123 Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof BEIJING TIDE PHARMACEUTICAL CO., LTD. 05/31/202D 3D TSV
US10335402 23 23 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders Takeda Pharmaceutical Company Limited 05/31/202D 3D TSV
USRE47451 45 9 HGNC:2433 HGNC:2730 HGNC:2731 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases Hanmi Pharm. Co. Ltd. 05/31/202D 3D TSV
US10011588 308 149 HGNC:4849 HGNC:4848 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED 05/26/202D 3D TSV
US10011627 18 9 HGNC:11037 HGNC:11036 C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof YOUNGENE THERAPEUTICS CO., LTD 05/26/202D 3D TSV
US10011599 101 99 HGNC:6840 Compounds and compositions as inhibitors of MEK Novartis AG 05/26/202D 3D TSV
US10011568 40 21 HGNC:11526 HGNC:2637 Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. 05/26/202D 3D TSV
US10011595 242 120 HGNC:4849 HGNC:4848 Ethyldiamine orexin receptor antagonists Merck Sharp & Dohme Corp. 05/26/202D 3D TSV
US10011607 111 111 HGNC:4596 Ethynyl derivatives Hoffman-La Roche Inc. 05/26/202D 3D TSV
US10011593 16 13 HGNC:6307 HGNC:8804 HGNC:9437 Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 05/26/202D 3D TSV
US10011611 44 4 HGNC:4852 HGNC:14064 HGNC:19086 HGNC:14068 HGNC:13315 HGNC:4853 HGNC:18128 Histone deacetylase inhibitors and methods for use thereof REACTION BIOLOGY CORP. 05/26/202D 3D TSV
US10011604 60 60 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma, Inc. 05/26/202D 3D TSV
US10010547 147 147 HGNC:1925 Pharmaceutical compounds Cascadian Therapeutics, Inc. 05/26/202D 3D TSV
US10011571 26 3 HGNC:6190 HGNC:3763 HGNC:6192 HGNC:1057 HGNC:6193 HGNC:6171 HGNC:11584 HGNC:12440 HGNC:3767 Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. 05/26/202D 3D TSV
US10010539 216 108 HGNC:4848 Pyrazole, triazole and tetrazole orexin receptor antagonists Merck Sharp & Dohme Corp. 05/26/202D 3D TSV
US10005769 79 78 HGNC:3092 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors 4SC AG 05/18/202D 3D TSV
US10005792 140 135 HGNC:10894 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors CTXT PTY. LTD. 05/18/202D 3D TSV
US10005788 52 24 HGNC:7027 HGNC:12446 Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation 05/18/202D 3D TSV
US10005768 136 135 HGNC:10597 Carboxamide derivatives and use thereof Purdue Pharma L.P. 05/18/202D 3D TSV
US10004738 49 48 HGNC:933 Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines H. Lundbeck A/S 05/18/202D 3D TSV
US10005735 104 40 HGNC:2240 HGNC:16889 Inhibitors of RPN11 California Institute of Technology; The Regents of the University of California 05/18/202D 3D TSV
US10005783 105 105 HGNC:8031 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Array BioPharma Inc. 05/18/202D 3D TSV
US10005762 159 80 HGNC:6656 Pyridine derivatives Astellas Pharma Inc.; KOTOBUKI PHARMACEUTICAL CO., LTD. 05/18/202D 3D TSV
US10005756 77 76 HGNC:16672 Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH 05/18/202D 3D TSV
US10005739 214 213 HGNC:2730 Quinazolinone and isoquinolinone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA 05/18/202D 3D TSV
US10005782 218 200 HGNC:1133 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. 05/18/202D 3D TSV
US10004755 149 40 HGNC:7027 HGNC:12446 HGNC:3765 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill 05/18/202D 3D TSV
US10329256 159 43 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Oryzon Genomics, S.A. 05/11/202D 3D TSV
US10323042 246 64 HGNC:8781 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds Pfizer Inc. 05/11/202D 3D TSV
US10323060 37 34 HGNC:7967 Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. 05/11/202D 3D TSV
US10000483 117 27 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:11719 HGNC:7972 HGNC:3942 Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof Dana-Farber Cancer Institute, Inc.; Beth Israel Deaconess Medical Center, Inc. 05/11/202D 3D TSV
US9999624 8 8 HGNC:933 Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor Eli Lilly and Company 05/11/202D 3D TSV
US10000507 426 142 HGNC:19310 HGNC:8987 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors Incyte Corporation 05/11/202D 3D TSV
US10000487 21 13 HGNC:7110 HGNC:7111 Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers eFFECTOR Therapeutics, Inc. 05/11/202D 3D TSV
US10323032 332 111 HGNC:8537 P2X7 Modulators Janssen Pharmaceutica NV 05/11/202D 3D TSV
US9999619 794 387 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors Incyte Holdings Corporation; Incyte Corporation 05/11/202D 3D TSV
USRE47437 55 24 HGNC:1232 HGNC:12680 HGNC:14661 Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics, Inc. 05/11/202D 3D TSV
US10000468 22 21 HGNC:4515 Pyrazines as modulators of GPR6 Takeda Pharmaceutical Company Limited 05/11/202D 3D TSV
US10323038 290 143 Pyrazole compounds and methods of making and using same ABIDE THERAPEUTICS, INC. 05/11/202D 3D TSV
US10000476 229 150 HGNC:7160 HGNC:195 HGNC:7173 HGNC:7163 HGNC:7175 HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7159 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. 05/11/202D 3D TSV
US10328074 61 61 Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors Boehringer Ingelheim International GmbH 05/11/202D 3D TSV
US10328054 69 69 Substituted pyrrolidines as mGluR5 antagonists Hua Medicine (Shanghai) Ltd. 05/11/202D 3D TSV
US10328053 138 135 HGNC:10905 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. 05/11/202D 3D TSV
US10323036 218 217 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 05/11/202D 3D TSV
US10329273 24 22 HGNC:7045 Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors Bristol-Myers Squibb Company 05/11/202D 3D TSV
US10328077 121 118 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas Celgene Corporation 05/11/202D 3D TSV
US10000475 14 14 HGNC:10597 Triazine carboxamides as sodium channel blockers Purdue Pharma L.P. 05/11/202D 3D TSV
US10329280 3 3 HGNC:6307 Urea derivatives and uses thereof Kala Pharmaceuticals, Inc. 05/11/202D 3D TSV
US10322118 24 21 HGNC:3402 Compounds and methods for inhibiting Cif virulence factor TRUSTEES OF DARTMOUTH COLLEGE; THE REGENTS OF TE UNIVERSITY OF CALIFORNIA 05/10/202D 3D TSV
US10323016 48 22 HGNC:19680 Imidazol- or 1,2,4-triazol-derivatives and their use UNIVERSITE DE LILLE 2 DROIT ET SANTE; INSTITUT PASTEUR DE LILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) 05/10/202D 3D TSV
US10323000 355 196 HGNC:5992 HGNC:8537 Indole derivatives and their use in neurodegenerative diseases Merck Patent GmbH 05/10/202D 3D TSV
US10322143 63 61 HGNC:220 HGNC:221 Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure UNIVERSITETET I OSLO 05/10/202D 3D TSV
US10322108 46 46 HGNC:10260 N-benzoate group substituted benzopyrroline-2-one derivative and use thereof Beijing Hanmi Pharmaceutical Co., Ltd. 05/10/202D 3D TSV
US10322140 24 13 HGNC:2637 HGNC:3537 Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists TBA 05/10/202D 3D TSV
US10323019 18 6 HGNC:6190 HGNC:6192 HGNC:6193 Pyrazolylaminobenzimidazole derivatives as JAK inhibitors Eli Lilly and Company 05/10/202D 3D TSV
US10323022 648 638 HGNC:8031 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors Array BioPharma Inc. 05/10/202D 3D TSV
US10323018 229 227 HGNC:30092 Quinazoline and quinoline compounds and uses thereof Millennium Pharmaceuticals, Inc. 05/10/202D 3D TSV
US10323023 19 19 HGNC:10252 Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof Beijing Tide Pharmaceutical Co., Ltd. 05/10/202D 3D TSV
US10323029 995 365 HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders The Scripps Research Institute 05/10/202D 3D TSV
US10323020 15 13 HGNC:283 Substituted piperidinyl tetrahydroquinolines BAYER PHARMA AKTIENGESELLSCHAFT 05/10/202D 3D TSV
US10323021 206 114 HGNC:6251 Triazoles as NR2B receptor inhibitors JANSSEN PHARMACEUTICALS, INC. 05/10/202D 3D TSV
US9994571 22 11 HGNC:8154 HGNC:8156 10-substituted morphinan hydantoins Purdue Pharma L.P. 05/07/202D 3D TSV
US9993478 104 32 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors Respivert, Ltd. 05/05/202D 3D TSV
US9993465 57 10 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof Georgetown University; Duke University 05/05/202D 3D TSV
US9994552 278 138 HGNC:6342 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION 05/05/202D 3D TSV
US9994546 130 129 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 05/05/202D 3D TSV
US9994525 16 16 H3 antagonists containing phenoxypiperidine core structure Richter Gedeon Nyrt. 05/05/202D 3D TSV
US9994547 150 149 HGNC:11584 Heteroarylamide inhibitors of TBK1 Takeda Pharmaceutical Company Limited 05/05/202D 3D TSV
US9994550 8 8 HGNC:3594 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections 3-V Biosciences, Inc. 05/05/202D 3D TSV
US9994590 59 54 HGNC:8772 Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors SUNOVION PHARMACEUTICALS INC. 05/05/202D 3D TSV
US9994576 33 33 HGNC:1133 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors PRINCIPIA BIOPHARMA INC. 05/05/202D 3D TSV
US9993479 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 05/05/202D 3D TSV
US9988392 21 13 HGNC:8154 HGNC:8156 7-beta-alkyl analogs of orvinols PURDUE PHARMA L.P. 04/30/202D 3D TSV
US9987274 135 47 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists OGEDA SA 04/30/202D 3D TSV
US9987255 48 24 HGNC:4849 HGNC:4848 5,5-bicyclic oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 04/25/202D 3D TSV
US9987253 8 8 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes JENRIN DISCOVERY, INC. 04/25/202D 3D TSV
US9988375 36 33 Inhibitors of lysine gingipain CORTEXYME, INC. 04/25/202D 3D TSV
US9987259 31 31 HGNC:1960 Pharmaceutical composition comprising pyridone derivatives SK BIOPHARMACEUTICALS CO., LTD. 04/25/202D 3D TSV
US9987278 41 41 Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof FUJIFILM Corporation 04/25/202D 3D TSV
US9987252 5 5 Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. 04/25/202D 3D TSV
US9987276 467 239 HGNC:1079 HGNC:6193 HGNC:6171 HGNC:3236 Substituted 2,4-diaminopyrimidines as kinase inhibitors Celgene CAR LLC 04/25/202D 3D TSV
US9981963 29 29 HGNC:1974 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors Janssen Pharmaceutica NV 04/18/202D 3D TSV
US9981944 245 124 HGNC:11773 GDF-8 inhibitors RIGEL PHARMACEUTICALS, INC; BRISTOL-MYERS SQUIBB COMPANY 04/18/202D 3D TSV
US9981901 75 73 HGNC:3449 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. 04/18/202D 3D TSV
US9981975 438 146 HGNC:7027 HGNC:12446 Pyrrolotriazine compounds as tam inhibitors Incyte Corporation 04/18/202D 3D TSV
US9981909 592 296 HGNC:5301 HGNC:11050 HGNC:5295 HGNC:5294 Serotonin receptor modulators Janssen Pharmaceutica NV 04/18/202D 3D TSV
US9981925 150 74 HGNC:391 HGNC:10436 Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors Merck Patent GmbH 04/18/202D 3D TSV
US9981950 116 116 HGNC:6251 Triazoles as NR2B receptor inhibitors JANSSEN PHARMACEUTICALS, INC. 04/18/202D 3D TSV
US9981973 20 10 HGNC:11708 HGNC:6059 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization NEWLINK GENETICS CORPORATION 04/18/202D 3D TSV
US9980929 73 73 Trifluoromethylpropanamide derivatives Hoffman-La Roche Inc. 04/18/202D 3D TSV
US10314832 18 17 HGNC:2514 β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators Samumed, LLC 04/15/202D 3D TSV
US10308635 23 23 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors Takeda Pharmaceutical Company Limited 04/15/202D 3D TSV
US10308629 47 40 HGNC:1148 1H-pyrrol-3-amines BAYER PHARMA AKTIENGESELLSCHAFT 04/15/202D 3D TSV
US10307427 23 18 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. 04/15/202D 3D TSV
US10308636 80 80 HGNC:2843 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION 04/15/202D 3D TSV
US10308660 171 170 HGNC:9644 Compounds and compositions for inhibiting the activity of SHP2 Novartis AG 04/15/202D 3D TSV
US10308607 3 3 HGNC:4006 Fucosidase inhibitors HORIZON ORPHAN LLC 04/15/202D 3D TSV
US10308628 10 10 HGNC:338 Heterocyclic compounds and methods for their use NOVARTIS AG 04/15/202D 3D TSV
US10308644 271 267 Heterocyclic compounds as immunomodulators Incyte Corporation 04/15/202D 3D TSV
US10308615 344 163 Heterocyclic compounds as inhibitors of Vanin-1 enzyme Pfizer Inc. 04/15/202D 3D TSV
US10308663 3 3 HGNC:9636 Inhibitors of PTP4A3 for the treatment of cancer University of Virginia Patent Foundation; University of Pittsburgh —Of the Commonwealth System of Higher Education 04/15/202D 3D TSV
US10308648 15 15 HGNC:1778 Inhibitors of cyclin-dependent kinase 7 (CDK7) Syros Pharmaceuticals, Inc. 04/15/202D 3D TSV
US10314827 21 18 HGNC:441 Methods of use of cyclopamine analogs Infinity Pharmaceuticals, Inc. 04/15/202D 3D TSV
US10308620 74 74 HGNC:1950 Muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED 04/15/202D 3D TSV
US10308667 168 167 HGNC:32311 Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors Boehringer Ingelheim International GmbH 04/15/202D 3D TSV
US10308645 86 43 HGNC:4849 HGNC:4848 Piperidine oxadiazole and thiadiazole orexin receptor antagonists Merck Sharp & Dohme Corp. 04/15/202D 3D TSV
US10308654 32 18 HGNC:1722 Preparation and use of kinase inhibitor CHANGZHOU LONGTHERA PHARMACEUTICALS INC. 04/15/202D 3D TSV
US10308605 14 14 Proton pump inhibitors Takeda Pharmaceutical Company Limited 04/15/202D 3D TSV
US10308659 246 121 HGNC:2160 HGNC:2159 Pyridine derivatives HOFFMANN-LA ROCHE INC. 04/15/202D 3D TSV
US10307414 35 34 HGNC:1133 Pyridinyl and fused pyridinyl triazolone derivatives Takeda Pharmaceutical Company Limited 04/15/202D 3D TSV
US10308634 22 22 HGNC:17967 Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs BAYER PHARMA AKTIENGESELLSCHAFT 04/15/202D 3D TSV
US10307413 679 673 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme, Inc. 04/15/202D 3D TSV
US10307426 36 16 HGNC:6190 HGNC:6192 Therapeutic compounds and compositions, and methods of use thereof Genentech, Inc. 04/15/202D 3D TSV
US10308614 304 238 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 04/15/202D 3D TSV
US10308637 319 310 HGNC:6863 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 04/15/202D 3D TSV
US10308662 114 28 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Thienopyranones as kinase and epigenetic inhibitors Signal Rx Pharmaceuticals., Inc. 04/15/202D 3D TSV
US10308652 64 60 HGNC:11892 Tricyclic heterocyclic compounds useful as inhibitors of TNF Bristol-Myers Squibb Company 04/15/202D 3D TSV
US9975876 63 31 HGNC:4849 HGNC:4848 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists Merck Sharp & Dohme Corp. 04/10/202D 3D TSV
US9974785 36 36 HGNC:5301 Aromatic heterocyclic derivatives and pharmaceutical applications thereof Sunshine Lake Pharma Co., Ltd. 04/10/202D 3D TSV
US9975862 12 2 HGNC:3023 HGNC:5286 Arylpiperazine derivatives and methods of utilizing same Reviva Pharmaceuticals, Inc. 04/10/202D 3D TSV
US9975858 10 10 HGNC:10597 Benzimidazole derivatives and use thereof Purdue Pharma L.P. 04/10/202D 3D TSV
US9975854 3 3 HGNC:8154 Benzomorphan analogs and use thereof Purdue Pharma L.P. 04/10/202D 3D TSV
US9975902 13 11 HGNC:9257 Compounds for the inhibition of cyclophilins and uses thereof Merck Patent GmbH 04/10/202D 3D TSV
US9975861 11 4 HGNC:933 HGNC:4617 Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer''s disease FONDAZIONE ISTITUTO ITAIANO DI TECNOLOGIA; ALMA MATER STUDIORUM—UNIVERSITA''DI BOLOGNA 04/10/202D 3D TSV
US9975874 86 44 HGNC:6371 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 04/10/202D 3D TSV
US9975882 212 63 HGNC:1079 HGNC:1133 HGNC:11719 HGNC:12434 Heteroaromatic compounds as BTK inhibitors Boehringer Ingelheim International GmbH 04/10/202D 3D TSV
US9975907 123 80 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Pyrimidinones as PI3K inhibitors Incyte Holdings Corporation; Incyte Corporation 04/10/202D 3D TSV
US9969723 53 50 HGNC:4498 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient HYUNDAI PHARM CO., LTD 04/06/202D 3D TSV
US9969687 122 122 HGNC:1610 Compounds useful as CCR9 modulators Norgine B.V. 04/06/202D 3D TSV
US9969724 53 53 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme Corp.; Mochida Pharmaceutical Co., Ltd. 04/06/202D 3D TSV
US9969749 169 166 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 04/06/202D 3D TSV
US9969726 724 190 Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 04/06/202D 3D TSV
US9969738 28 6 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders OGEDA SA 04/06/202D 3D TSV
US9969700 8 8 HGNC:8535 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. 04/06/202D 3D TSV
US9968610 15 10 HGNC:6251 HGNC:2625 Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 04/06/202D 3D TSV
US9969686 9 9 HGNC:348 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them Wisconsin Alumni Research Foundation 04/06/202D 3D TSV
US9969743 260 130 HGNC:3023 HGNC:3024 Urea and amide derivatives of aminoalkylpiperazines and use thereof SOUTHERN RESEARCH INSTITUTE 04/06/202D 3D TSV
US9963460 3 1 HGNC:8153 HGNC:8154 HGNC:8156 Morphinan derivative University of Tsukuba; Nippon Chemiphar Co., Ltd. 03/30/202D 3D TSV
US9963444 117 117 HGNC:736 N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof Northeastern University 03/30/202D 3D TSV
US9963434 220 220 N-arylmethyl sulfonamide negative modulators of NR2A Luc Therapeutics, Inc. 03/30/202D 3D TSV
US9963446 26 26 Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use Genentech, Inc. 03/30/202D 3D TSV
US9963456 40 40 HGNC:1373 Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd 03/30/202D 3D TSV
US9962388 45 45 HGNC:15631 Pyrrolopyrimidine compounds used as TLR7 agonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. 03/30/202D 3D TSV
US9963443 13 13 Radiolabeled compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED 03/30/202D 3D TSV
US9963439 46 18 HGNC:2637 HGNC:20581 HGNC:2603 HGNC:2622 HGNC:2623 Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase University of Washington Through Its Center For Commercialization; University of Montana 03/30/202D 3D TSV
US9963453 45 43 HGNC:8157 Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators LABORATORIOS DEL DR. ESTEVE S.A. 03/30/202D 3D TSV
US9962398 60 15 HGNC:1373 HGNC:1383 HGNC:1371 HGNC:1368 Sulfonamide compounds for inhibition of metastatic tumor growth Welichem Biotech Inc. 03/30/202D 3D TSV
US9962362 18 12 HGNC:3521 HGNC:9642 Use of small molecule inhibitors targeting EYA tyrosine phosphatase Children''s Hospital Medical Center 03/30/202D 3D TSV
US10301320 27 25 HGNC:5154 Compositions and methods of modulating 15-PGDH activity University of Kentucky Research Foundation; Case Western Reserve University; Board of Regents of the University of Texas System 03/26/202D 3D TSV
US10301305 252 63 Heteroaromatic derivatives and their use as pharmaceuticals MUTABILIS 03/26/202D 3D TSV
US10301323 183 61 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. 03/26/202D 3D TSV
US10301291 31 31 HGNC:6872 Imidazole derivative having JNK inhibitory activity and use thereof SAMJIN PHARMACEUTICAL CO., LTD. 03/26/202D 3D TSV
US10301317 373 365 HGNC:6871 Inhibitors of ERK and methods of use KURA ONCOLOGY, INC. 03/26/202D 3D TSV
US10301288 61 15 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Topivert Pharma Limited 03/26/202D 3D TSV
US10301336 33 33 HGNC:2771 Phosphonate compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 03/26/202D 3D TSV
US10301286 79 33 HGNC:6932 HGNC:6929 HGNC:6931 Piperazine derivative Astellas Pharma Inc. 03/26/202D 3D TSV
US10301306 185 180 HGNC:10021 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors Bristol-Myers Squibb Company 03/26/202D 3D TSV
US10301297 63 62 HGNC:1133 Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease Guangzhou Innocare Pharma Tech Co., Ltd. 03/26/202D 3D TSV
US10301284 141 139 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 03/26/202D 3D TSV
US10301278 58 54 HGNC:9644 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 Novartis AG 03/25/202D 3D TSV
US10300056 14 14 HGNC:9843 CGRP receptor antagonists Heptares Therapeutics Limited 03/25/202D 3D TSV
US10301272 844 306 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] Phenex Pharmaceuticals AG 03/25/202D 3D TSV
US10301280 257 153 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 03/25/202D 3D TSV
US10300051 61 61 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/25/202D 3D TSV
US10301269 41 41 HGNC:3827 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. 03/25/202D 3D TSV
US10300066 119 118 HGNC:1133 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Zhejiang DTRM Biopharma Co. Ltd. 03/25/202D 3D TSV
US10300067 53 53 HGNC:644 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 03/25/202D 3D TSV
US10301253 203 87 HGNC:29079 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 03/25/202D 3D TSV
US10300048 73 53 HGNC:3553 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation UNIVERSITAT BERN 03/25/202D 3D TSV
US10300060 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 03/25/202D 3D TSV
US10300058 50 18 HGNC:3236 Tyrosine kinase inhibitor and uses thereof Xuanzhu Pharma Co., Ltd. 03/25/202D 3D TSV
US10300074 114 40 HGNC:13702 Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; SALK INSTITUTE FOR BIOLOGICAL STUDIES 03/25/202D 3D TSV
US9957268 196 88 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 03/23/202D 3D TSV
US9956214 208 103 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum University of Washington Through its Center for Commercialization 03/23/202D 3D TSV
US9957261 118 59 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives Hoffman-La Roche Inc. 03/23/202D 3D TSV
US9957235 248 139 Benzimidazol-2-amines as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 03/23/202D 3D TSV
US9957263 371 184 HGNC:13575 Bromodomain inhibitors AbbVie Inc. 03/23/202D 3D TSV
US9957276 44 44 HGNC:1771 CDK inhibitors GI Therapeutics, Inc. 03/23/202D 3D TSV
US9956208 4 4 HGNC:1133 Compounds for the treatment of cancer and inflammatory diseases TBA 03/23/202D 3D TSV
US9957264 938 423 HGNC:6190 HGNC:6192 Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors Merck Sharp & Dohme Corp. 03/23/202D 3D TSV
US9957265 226 75 HGNC:6190 HGNC:6192 N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors Merck Sharp & Dohme Corp. 03/23/202D 3D TSV
US9956192 42 21 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of The University of Illinois 03/23/202D 3D TSV
US9951056 63 61 HGNC:1133 Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease BEIJING INNOCARE PHARMA TECH CO., LTD. 03/18/202D 3D TSV
US9951063 147 147 HGNC:4540 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives IDORSIA PHARMACEUTICALS LTD 03/16/202D 3D TSV
US9951077 118 116 HGNC:1133 Aminopyridazinone compounds as protein kinase inhibitors Jiangsu Hengrui Medicine Co., Ltd. 03/16/202D 3D TSV
US9951027 390 346 Benzimidazol-2-amines as MIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 03/16/202D 3D TSV
US9951071 443 219 HGNC:6371 HGNC:3529 Dihydropyridone P1 as factor XIa inhibitors Bristol-Myers Squibb Company 03/16/202D 3D TSV
US9951026 13 13 HGNC:3357 Heterocyclic vinyl autotaxin inhibitor compounds PHARMAKEA, INC. 03/16/202D 3D TSV
US9951068 271 154 HGNC:6251 HGNC:550 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED 03/16/202D 3D TSV
US9951086 310 305 HGNC:17967 Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments BAYER PHARMA AKTIENGESELLSCHAFT 03/16/202D 3D TSV
US9949975 25 25 HGNC:933 Inhibitors of beta-secretase Vitae Pharmaceuticals, Inc. 03/16/202D 3D TSV
US9951048 488 236 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 03/16/202D 3D TSV
US9951014 113 35 HGNC:7872 HGNC:7873 Mammalian and bacterial nitric oxide synthase inhibitors Northwestern University 03/16/202D 3D TSV
US9949951 29 28 HGNC:6059 Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors ITEOS THERAPEUTICS 03/16/202D 3D TSV
US9951035 6 3 HGNC:7175 HGNC:7176 Selective matrix metalloproteinase inhibitors University of Notre Dame du Lac 03/16/202D 3D TSV
US9951029 63 63 HGNC:3765 Styryl quinazoline derivatives as pharmaceutically active agents Vichem Chemie Kutató Kft. 03/16/202D 3D TSV
US9951033 23 23 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO 03/16/202D 3D TSV
US9944601 159 43 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors ORYZON GENOMICS, S.A. 03/12/202D 3D TSV
US9944646 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Holdings Corporation; Incyte Corporation 03/12/202D 3D TSV
US9944606 9 5 HGNC:2160 HGNC:2159 Cannabinoid receptor modulators Arena Pharmaceuticals, Inc. 03/12/202D 3D TSV
US9944643 8 8 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 03/12/202D 3D TSV
US9944647 138 138 HGNC:29079 Heterocyclic compounds as LSD1 inhibitors Incyte Corporation 03/12/202D 3D TSV
US9944645 205 205 HGNC:7029 Imidazotriazines and imidazopyrimidines as kinase inhibitors Incyte Corporation; Incyte Holdings Corporation 03/12/202D 3D TSV
US9944618 940 167 HGNC:6251 HGNC:11050 HGNC:2637 HGNC:2625 HGNC:11048 HGNC:11049 Inhibiting neurotransmitter reuptake Mayo Foundation for Medical Education and Research; Virginia Tech Intellectual Properties, Inc. 03/12/202D 3D TSV
US9943516 19 17 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 03/12/202D 3D TSV
USRE46792 103 103 HGNC:8783 Oxazole compound and pharmaceutical composition Otsuka Pharmaceutical Co., Ltd. 03/12/202D 3D TSV
US9944624 126 61 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics S.A. 03/12/202D 3D TSV
US10294221 63 57 1, 3, 4-thiadiazole compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 03/10/202D 3D TSV
US10294230 48 11 HGNC:4586 HGNC:6251 HGNC:2625 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 03/10/202D 3D TSV
US10294218 165 150 HGNC:1780 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity VIROSTATICS SRL 03/10/202D 3D TSV
US10294227 332 21 HGNC:11283 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:1057 HGNC:76 HGNC:6342 HGNC:3955 HGNC:3942 HGNC:9967 HGNC:6524 Compounds UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH 03/10/202D 3D TSV
US10292975 2 2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 03/10/202D 3D TSV
US10294217 35 27 HGNC:1950 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators Suven Life Sciences Limited 03/10/202D 3D TSV
US10294229 444 398 HGNC:17967 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Company 03/10/202D 3D TSV
US10294212 277 273 HGNC:27269 HGNC:6059 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. 03/10/202D 3D TSV
US10292981 53 47 HGNC:6001 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED 03/10/202D 3D TSV
US10294259 6 3 HGNC:11037 HGNC:11036 Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof Tianjin Institute of Pharmaceutical Research 03/10/202D 3D TSV
US10294214 80 80 HGNC:6932 Positive allosteric modulators of human melanocortin-4 receptor Vanderbilt University; King''s College London; Glaxo Group Limited 03/10/202D 3D TSV
US10294223 197 129 HGNC:3689 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. 03/10/202D 3D TSV
US10294226 60 15 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 03/10/202D 3D TSV
US10294246 271 135 HGNC:9542 HGNC:9545 Substituted boronic acids and boronate esters as immunoproteasome inhibitors MERCK PATENT GMBH 03/10/202D 3D TSV
US10292985 72 36 HGNC:11772 HGNC:11773 TGF beta receptor antagonists Bristol-Myers Squibb Company 03/10/202D 3D TSV
US9938265 43 33 1,3,4-thiadiazole compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 03/02/202D 3D TSV
US9938276 164 81 HGNC:4849 HGNC:4848 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists Merck Sharp & Dohme Corp. 03/02/202D 3D TSV
US9938268 34 34 HGNC:11393 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof Merck Patent GmbH 03/02/202D 3D TSV
US9938222 129 116 HGNC:19061 Cyclopropanecarboxylic acid GPR120 modulators Bristol-Myers Squibb Company 03/02/202D 3D TSV
US9938267 694 668 Heterocyclic inhibitors of glutaminase Calithera Biosciences, Inc. 03/02/202D 3D TSV
US9938272 109 34 HGNC:9475 HGNC:3528 HGNC:3535 Hydrazine compound as blood coagulation factor Xa inhibitor North China Pharmaceutical Company., Ltd. 03/02/202D 3D TSV
US9938274 44 22 HGNC:6307 HGNC:7029 Naphthyridine compounds, medical combinations and use thereof NANJING NATINEFY PHARMATECH CO., LTD.; WUHAN NOVAFFEY SCIENCE & TECHNOLOGY CO., LTD. 03/02/202D 3D TSV
US9938257 57 25 HGNC:6190 HGNC:6192 HGNC:11393 HGNC:11390 HGNC:3765 Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD. 03/02/202D 3D TSV
US9938289 9 9 HGNC:11772 Therapeutic pyrazolyl thienopyridines FBM THERAPEUTICS, LLC 03/02/202D 3D TSV
US9938290 52 13 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Karus Therapeutics Limited 03/02/202D 3D TSV
US10287286 262 260 HGNC:14660 Compounds Takeda Pharmaceutical Company Limited 02/29/202D 3D TSV
US9931340 68 66 HGNC:2671 Pyridazinone compounds and their use as DAAO inhibitors Takeda Pharmaceutical Company Limited 02/29/202D 3D TSV
US10285983 70 70 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10285982 66 66 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10287274 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 02/27/202D 3D TSV
US10287270 3 3 HGNC:550 Amino pyrimidine SSAO inhibitors ELI LILLY AND COMPANY 02/27/202D 3D TSV
US10287301 719 698 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 02/27/202D 3D TSV
US10287293 45 22 HGNC:8777 Bicyclic heterocyclic compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287292 184 129 HGNC:23692 CXCR7 antagonists ChemoCentryx, Inc. 02/27/202D 3D TSV
US10287258 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 02/27/202D 3D TSV
US10287278 40 14 HGNC:6026 HGNC:6027 Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies GALDERMA RESEARCH & DEVELOPMENT 02/27/202D 3D TSV
US10285988 30 30 HGNC:15983 Compounds for treatment of fibrosis diseases CUREGENIX, INC. 02/27/202D 3D TSV
US10287300 130 64 HGNC:28426 Heterocyclic derivatives as modulators of kinase activity Merck Patent GmbH 02/27/202D 3D TSV
US10287268 8 4 HGNC:4840 HGNC:1133 Imidazolyl kinase inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. 02/27/202D 3D TSV
US10287279 42 39 HGNC:433 Inhibitors of human 12/15-lipoxygenase THE CHILDREN''S HOSPITAL CORPORATION; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services 02/27/202D 3D TSV
US10287267 951 304 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 02/27/202D 3D TSV
US10287250 110 35 HGNC:8156 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED 02/27/202D 3D TSV
US10285989 371 197 HGNC:8777 Pyrimidinone amide compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287272 149 126 HGNC:10260 Substituted indazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 02/27/202D 3D TSV
US10287305 266 261 HGNC:4849 Substituted piperidine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 02/27/202D 3D TSV
US10287253 52 51 HGNC:15631 Substituted pyrimidines containing acidic groups as TLR7 modulators APROS THERAPEUTICS, INC. 02/27/202D 3D TSV
US10287295 605 303 HGNC:11773 TGF-β inhibitors Rigel Pharmaceuticals, Inc.; Bristol-Meyers Squibb Company 02/27/202D 3D TSV
US10280166 126 125 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof Samumed, LLC 02/24/202D 3D TSV
US9932329 28 14 HGNC:6171 HGNC:12434 Benzimidazole derivatives as RLK and ITK inhibitors PRINCIPIA BIOPHARMA, INC. 02/24/202D 3D TSV
US9932325 215 166 Compounds, compositions, and methods Denali Therapeutics Inc. 02/24/202D 3D TSV
US9932332 2 2 HGNC:7967 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. 02/24/202D 3D TSV
US10280171 183 98 HGNC:3255 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 02/24/202D 3D TSV
US10280184 71 69 HGNC:1133 HGNC:2433 Heterocyclic kinase inhibitors AbbVie Inc. 02/24/202D 3D TSV
US9932350 108 101 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 02/24/202D 3D TSV
US10280167 39 39 Purine derivatives for the treatment of viral infections Janssen Sciences Ireland UC 02/24/202D 3D TSV
US9932327 10 5 HGNC:1780 HGNC:1771 Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof The Council of Scientific & Industrial Research 02/24/202D 3D TSV
US9931338 7 7 HGNC:11491 Syk inhibitors Gilead Sciences, Inc. 02/24/202D 3D TSV
US9932341 125 112 HGNC:8977 Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders Incyte Corporation; Incyte Holdings Corporation 02/24/202D 3D TSV
US10278968 15 15 Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. 02/21/202D 3D TSV
US10278929 41 36 HGNC:12405 Identification of stabilizers of multimeric proteins The Board of Trustees of the Leland Stanford Junior University 02/21/202D 3D TSV
US10280160 31 26 HGNC:1884 Phthalazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC 02/21/202D 3D TSV
US10280164 16 16 HGNC:6863 Pyrazolopyridone compounds and uses thereof Incyte Corporation 02/21/202D 3D TSV
US10280144 213 213 HGNC:10260 Pyridazine derivatives as RORc modulators Genentech, Inc. 02/21/202D 3D TSV
US10280165 40 40 Pyridopyrimidinones and methods of use thereof Genentech, Inc. 02/21/202D 3D TSV
US10280150 297 183 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 02/21/202D 3D TSV
US10280174 3 2 HGNC:1133 HGNC:3236 Salt of fused pyrimidine compound and crystal thereof TAIHO PHARMACEUTICAL CO., LTD. 02/21/202D 3D TSV
US10278975 186 172 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 02/21/202D 3D TSV
US10280149 220 219 HGNC:13610 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 02/21/202D 3D TSV
US10278962 24 11 HGNC:11177 HGNC:11178 Tricyclic analogues, preparation method and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 02/21/202D 3D TSV
US10273234 26 26 HGNC:3357 Compounds that are S1P modulating agents and/or ATX modulating agents BIOGEN MA INC. 02/20/202D 3D TSV
US10273222 604 163 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors CELGENE QUANTSCEL RESEARCH, INC. 02/20/202D 3D TSV
US10272074 477 475 HGNC:7978 Inhibitors of glucocorticoid receptor translocation SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 02/20/202D 3D TSV
US10273211 24 5 HGNC:3763 HGNC:6307 HGNC:11390 HGNC:3767 HGNC:7029 HGNC:9967 HGNC:3765 Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Exelixis, Inc. 02/20/202D 3D TSV
US10272079 361 180 HGNC:11073 NHE3-binding compounds and methods for inhibiting phosphate transport ARDELYX, INC. 02/20/202D 3D TSV
US10272095 87 83 HGNC:2874 NRF2 regulators GlaxoSmithKline Intellectual Propert Development Limited; Astex Therapeutics, Limited 02/20/202D 3D TSV
US10272077 14 14 Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp. 02/20/202D 3D TSV
US10272087 50 8 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pteridines as FGFR inhibitors ASTEX THERAPEUTICS LTD 02/20/202D 3D TSV
US10273225 22 21 HGNC:4515 Pyrazines as modulators of GPR6 Takeda Pharmaceutical Company Limited 02/20/202D 3D TSV
US10273223 391 389 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 02/20/202D 3D TSV
US10273244 348 173 HGNC:3023 HGNC:3024 Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators INDIVIOR UK LIMITED 02/20/202D 3D TSV
US10273230 16 15 HGNC:19061 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof Piramal Enterprises Limited 02/20/202D 3D TSV
US10273214 78 39 HGNC:4588 HGNC:4587 HGNC:4586 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions Emory University 02/20/202D 3D TSV
US10273259 881 804 Tricyclic sulfones as RORγ modulators Bristol-Myers Squibb Company 02/20/202D 3D TSV
US9890168 32 15 HGNC:3236 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof Shanghai Haiyan Pharmaceutical Technology Co., Ltd.; Yangtze River Pharmaceutical Group Co., Ltd. 02/16/202D 3D TSV
US9890171 200 130 HGNC:2592 Aldosterone synthase inhibitors Boehringer Ingelheim International GmbH 02/16/202D 3D TSV
US9890124 46 23 HGNC:15631 HGNC:15632 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc. 02/16/202D 3D TSV
US9890162 156 52 HGNC:19310 HGNC:8987 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890156 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890160 3 3 HGNC:550 Compounds I PROXIMAGEN LIMITED 02/16/202D 3D TSV
US9890166 638 168 HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 Imidazopyrrolidine derivatives and their use in the treatment of disease NOVARTIS AG 02/16/202D 3D TSV
US9890185 468 169 HGNC:11491 HGNC:11283 HGNC:4616 Urea derivatives useful as kinase inhibitors Respivert Limited; Topivert Pharma Limited 02/16/202D 3D TSV
US9926281 1937 451 HGNC:7160 HGNC:195 HGNC:7155 HGNC:7166 HGNC:7159 HGNC:221 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV; LES LABORATOIRES SERVIER 02/10/202D 3D TSV
US9926301 28 13 Bipyrazole derivatives as JAK inhibitors Incyte Corporation 02/10/202D 3D TSV
US9926306 34 33 Inhibition of MCL-1 and/or BFL-1/A1 Dana-Farber Cancer Institute, Inc. 02/10/202D 3D TSV
US9926330 55 53 HGNC:17967 Inhibitors of IRAK4 activity MERCK SHARP & DOHME CORP. 02/10/202D 3D TSV
US9926299 34 34 HGNC:1133 Inhibitors of bruton's tyrosine kinase Centaurus BioPharma Co., Ltd. 02/10/202D 3D TSV
US9926282 826 401 HGNC:10251 HGNC:10252 Phthalazinones and isoquinolinones as rock inhibitors Bristol-Myers Squibb Company 02/10/202D 3D TSV
US9926318 58 53 HGNC:3357 Tetracyclic autotaxin inhibitors PHARMAKEA, INC. 02/10/202D 3D TSV
USRE47351 11 11 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists Gilead Sciences, Inc. 02/07/202D 3D TSV
US10266528 23 22 HGNC:1133 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof Merck Patent GmbH 02/07/202D 3D TSV
US10266537 116 27 HGNC:6613 HGNC:3763 HGNC:11724 HGNC:6735 HGNC:4037 HGNC:3386 HGNC:5960 HGNC:6859 HGNC:9829 HGNC:3689 HGNC:6873 HGNC:7027 HGNC:3767 HGNC:2730 HGNC:7029 HGNC:3688 HGNC:2731 HGNC:6192 HGNC:8031 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:3430 HGNC:6307 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:3395 HGNC:77 HGNC:1097 HGNC:76 HGNC:3393 HGNC:3955 HGNC:3236 HGNC:2444 HGNC:1974 HGNC:6524 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof St. Chuan University 02/07/202D 3D TSV
US10265310 158 71 HGNC:3827 HGNC:3826 6-membered cyclic amines or lactames substituted with urea and phenyl GrÜNENTHAL GMBH 02/07/202D 3D TSV
US10266550 64 26 HGNC:11986 HGNC:11989 Bacterial topoisomerase I inhibitors with antibacterial activity THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES; UNIVERSITY OF HAWAII 02/07/202D 3D TSV
US10259818 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Corporation; Incyte Holdings Corporation 02/07/202D 3D TSV
US10266560 65 64 HGNC:7967 Bile acid analogs as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. 02/07/202D 3D TSV
US10259776 16 13 HGNC:4685 Branched 3-phenylpropionic acid derivatives and their use Bayer Intellectual Property GmbH 02/07/202D 3D TSV
US10266513 190 134 HGNC:1133 HGNC:3236 Bruton's tyrosine kinase inhibitors Pfizer Inc. 02/07/202D 3D TSV
US10266491 200 168 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Company 02/07/202D 3D TSV
US10266496 160 118 HGNC:12805 HGNC:17989 Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof SUNSHINE LAKE PHARMA CO., LTD. 02/07/202D 3D TSV
US10259816 26 26 HGNC:427 Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. 02/07/202D 3D TSV
US10266542 19 18 HGNC:3527 EZH2 inhibitors Mirati Therapeutics, Inc. 02/07/202D 3D TSV
US10266535 56 29 HGNC:1133 HGNC:3765 Inhibitor of FLT3 kinase and use thereof HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES; HEFEI COSOURCE PHARMACEUTICAL CO., LTD. 02/07/202D 3D TSV
US10259786 8 4 HGNC:3023 Psychotropic agents and uses thereof LB PHARMACEUTICALS INC. 02/07/202D 3D TSV
US10266526 956 932 HGNC:15513 HGNC:20982 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer EPIZYME, INC. 02/07/202D 3D TSV
US10266548 211 187 HGNC:1148 Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases Bayer Intellectual Property GmbH; Bayer Pharma Aktiengesellschaft 02/07/202D 3D TSV
US10259811 517 258 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. 02/07/202D 3D TSV
US10266515 202 144 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 02/07/202D 3D TSV
US10265307 324 106 HGNC:19310 HGNC:8987 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors Incyte Corporation; Incyte Holdings Corporation 02/07/202D 3D TSV
US10266493 71 70 HGNC:17989 Thioacetate compounds, compositions and methods of use Ardea Biosciences, Inc. 02/07/202D 3D TSV
US10266549 345 343 HGNC:12558 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY 02/07/202D 3D TSV
US9918985 181 155 Compounds and their use as BACE inhibitors ASTRAZENECA AB 02/04/202D 3D TSV
US9920047 375 109 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 02/04/202D 3D TSV
US9920032 510 168 HGNC:19310 HGNC:8987 Heterocyclic compounds useful as pim kinase inhibitors Incyte Corporation 02/04/202D 3D TSV
US9920031 261 218 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Company 02/04/202D 3D TSV
US9920038 62 30 HGNC:4849 Methyl oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 02/04/202D 3D TSV
US9920054 104 104 HGNC:10260 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof Pfizer Inc. 02/04/202D 3D TSV
US9920053 130 35 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system CHRONOS THERAPEUTICS LIMITED 02/04/202D 3D TSV
US9920060 80 79 HGNC:3430 Pyrazolo[3,4-d]pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 02/04/202D 3D TSV
US9918974 2 2 Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 02/04/202D 3D TSV
US9918969 16 14 HGNC:3529 Substituted oxopyridine derivatives and use thereof as factor XIa/plasma Bayer Pharma Aktiengesellschaft 02/04/202D 3D TSV
US9918990 226 111 HGNC:13575 HGNC:1103 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation 02/04/202D 3D TSV
US9914735 391 78 HGNC:11491 HGNC:11390 HGNC:4617 HGNC:3765 Heteroaryl Syk inhibitors Boehringer Ingelheim International GmbH 01/30/202D 3D TSV
US9914707 30 30 HGNC:6307 Naphthylamide compound, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 01/30/202D 3D TSV
US9914731 293 156 HGNC:7029 Pyrazolo[1,5-a]pyridine derivatives and methods of their use IGNYTA, INC. 01/30/202D 3D TSV
US9914736 114 113 HGNC:8031 TrKA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 01/30/202D 3D TSV
US9914740 420 404 HGNC:10252 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Bristol-Myers Squibb Company 01/30/202D 3D TSV
US9914721 22 11 HGNC:4849 HGNC:4848 Use of benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD 01/30/202D 3D TSV
US9908875 45 45 HGNC:6857 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. 01/27/202D 3D TSV
US9908845 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/27/202D 3D TSV
US9908886 266 132 HGNC:7110 HGNC:7111 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof Agency for Science, Technology and Research 01/27/202D 3D TSV
US9908899 143 48 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. 01/27/202D 3D TSV
US9908865 511 154 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 01/27/202D 3D TSV
US9907800 460 198 HGNC:11393 HGNC:11390 HGNC:11397 HGNC:3765 Kinase inhibitors and method of treating cancer University Health Network 01/27/202D 3D TSV
US9908872 19 8 HGNC:1133 HGNC:4195 HGNC:7972 Methods to treat lymphoplasmacytic lymphoma Dana-Farber Cancer Institute, Inc. 01/27/202D 3D TSV
US9908897 306 84 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 Spirocyclic derivatives CHRONOS THERAPEUTICS LIMITED 01/27/202D 3D TSV
US9908895 196 88 HGNC:6190 HGNC:6192 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Corporation 01/27/202D 3D TSV
US10246444 134 32 HGNC:3432 HGNC:3430 HGNC:3236 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions SABILA BIOSCIENCES LLC 01/21/202D 3D TSV
US10246442 135 135 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 01/21/202D 3D TSV
US10253018 41 41 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. 01/21/202D 3D TSV
US9896418 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/21/202D 3D TSV
US9903855 20 5 HGNC:5960 HGNC:11584 HGNC:14552 HGNC:1974 Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 01/21/202D 3D TSV
US9896444 175 101 Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 Novartis AG 01/21/202D 3D TSV
US10246453 1146 330 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 01/21/202D 3D TSV
US9902722 237 235 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 01/21/202D 3D TSV
US10251892 856 186 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 01/21/202D 3D TSV
US10246462 92 88 HGNC:1605 Chemokine receptor modulators and uses thereof FLX BIO, INC. 01/21/202D 3D TSV
US9896458 251 243 Compounds, compositions and methods Denali Therapeutics Inc. 01/21/202D 3D TSV
US10253017 22 9 HGNC:7856 HGNC:263 HGNC:264 Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors PALOBIOFARMA, S.L. 01/21/202D 3D TSV
US10246466 54 18 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 Diaryl macrocycles as modulators of protein kinases TP Therapeutics, Inc. 01/21/202D 3D TSV
US9895376 116 57 Fused tricyclic compounds as Raf kinase inhibitors BEIGENE, LTD. 01/21/202D 3D TSV
US9896436 329 106 HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 01/21/202D 3D TSV
US10246456 686 509 HGNC:17967 IRAK4 inhibiting agents BIOGEN MA INC. 01/21/202D 3D TSV
US10253004 54 53 HGNC:4498 Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US10246457 56 28 HGNC:1133 Indazole and azaindazole Btk inhibitors Merck Sharp & Dohme Corp. 01/21/202D 3D TSV
US10252984 51 51 HGNC:4545 Inhibiting G protein coupled receptor 6 kinase polypeptides Mayo Foundation for Medical Education and Research 01/21/202D 3D TSV
US9902719 31 31 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 01/21/202D 3D TSV
US9902741 68 46 HGNC:8031 Macrocyclic compounds as TRK kinase inhibitors Array BioPharma Inc. 01/21/202D 3D TSV
US10251893 230 227 HGNC:15983 N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators Novartis AG 01/21/202D 3D TSV
US9896435 31 31 HGNC:8031 N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors Array BioPharma Inc. 01/21/202D 3D TSV
US9902709 13 13 HGNC:6307 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition PEKING UNIVERSITY FOUNDER GROUP CO., LTD.; PKUCARE PHARMACEUTICAL R & D CENTER; PKU HEALTHCARE INDUSTRY GROUP CO., LTD. 01/21/202D 3D TSV
US10253015 169 85 Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 01/21/202D 3D TSV
US9902726 5 4 HGNC:8154 HGNC:8156 Pyridone-sulfone morphinan analogs as opioid receptor ligands Purdue Pharma L.P. 01/21/202D 3D TSV
US9902714 35 7 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Quinoxaline derivatives useful as FGFR kinase modulators ASTEX THERAPEUTICS LTD 01/21/202D 3D TSV
US10246467 67 57 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US9902710 169 168 HGNC:8772 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) EXONHIT THERAPEUTICS, SA; ALLERGAN, INC. 01/21/202D 3D TSV
US9896452 703 365 HGNC:4849 HGNC:4848 Substituted prolines/piperidines as orexin receptor antagonists EOLAS THERAPEUTICS, INC. 01/21/202D 3D TSV
US10251889 530 232 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:12440 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharm Inc. 01/21/202D 3D TSV
US10253019 1854 609 HGNC:6192 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. 01/21/202D 3D TSV
US9896447 46 46 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 01/21/202D 3D TSV
US10238658 120 32 HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors RESPIVERT LIMITED 12/30/192D 3D TSV
US10239843 681 620 HGNC:8605 HGNC:270 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED 12/30/192D 3D TSV
US10246425 16 16 HGNC:10593 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds Parion Sciences, Inc. 12/30/192D 3D TSV
US10246432 25 22 HGNC:4597 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators Heptares Therapeutics Limited 12/30/192D 3D TSV
US10239883 665 132 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors Merck Sharp & Dohme B.V. 12/30/192D 3D TSV
US10239868 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 12/30/192D 3D TSV
US10239840 22 22 Benzoazepine derivatives VIIV HEALTHCARE UK LIMITED 12/30/192D 3D TSV
US10238638 48 48 Benzothiazole and benzothiophene compounds Universite De Montreal; Bristol-Myers Squibb Company 12/30/192D 3D TSV
US10245267 2564 1057 HGNC:9829 Biaryl amide compounds as kinase inhibitors Novartis AG 12/30/192D 3D TSV
US10238743 98 49 HGNC:934 HGNC:933 C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use TBA 12/30/192D 3D TSV
US10239870 462 190 HGNC:3023 Dopamine D3 receptor antagonists Indivior UK Limited 12/30/192D 3D TSV
US10239838 106 53 HGNC:4849 HGNC:4848 Heteroaryl orexin receptor antagonists Merck Sharp & Dohme Corp. 12/30/192D 3D TSV
US10246419 13 12 HGNC:7965 Liver X receptor (LXR) modulators RALEXAR THERAPEUTICS, INC. 12/30/192D 3D TSV
US10238633 584 357 HGNC:2528 Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C Boehringer Ingelheim International GmbH 12/30/192D 3D TSV
US10239835 142 141 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B CADENT THERAPEUTICS, INC. 12/30/192D 3D TSV
US10239887 97 75 HGNC:1953 Positive allosteric modulators of the muscarinic acetylcholine receptor M4 Vanderbilt University 12/30/192D 3D TSV
US10239881 26 25 HGNC:10020 RIPK2 inhibitors and method of treating cancer with same University Health Network 12/30/192D 3D TSV
US10239882 86 86 HGNC:8777 Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors DART NEUROSCIENCE (CAYMAN) LTD. 12/30/192D 3D TSV
US10239869 405 243 HGNC:10593 HGNC:10597 Sulfonamide compounds as voltage-gated sodium channel modulators LUPIN LIMITED 12/30/192D 3D TSV
US10239861 60 58 HGNC:8638 Therapeutic compounds and uses thereof GENETECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 12/30/192D 3D TSV
US10239876 170 169 HGNC:3020 Triaza-spirodecanones as DDR1 inhibitors Hoffman La-Roche Inc. 12/30/192D 3D TSV
US10246426 240 240 HGNC:1395 Triazole compounds as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD 12/30/192D 3D TSV
US10245275 158 76 Triterpenoids with HIV maturation inhibitory activity VIIV HEALTHCARE UK (NO. 4) LIMITED 12/30/192D 3D TSV
US10246429 755 248 HGNC:934 HGNC:2529 HGNC:933 Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use AMGEN INC. 12/30/192D 3D TSV
US10227299 295 287 HGNC:1148 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones BAYER PHARMA AKTIENGESELLSCHAFT 12/27/192D 3D TSV
US10233156 57 57 HGNC:85 9-membered fused ring derivative SHIONOGI & CO., LTD. 12/27/192D 3D TSV
US10233178 24 8 HGNC:6833 HGNC:6834 HGNC:29079 Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use Oryzon Genomics, S.A. 12/27/192D 3D TSV
US10226452 45 45 HGNC:735 Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments The Regents of the University of California; Fondazione Istituto Italiano di Tecnologia 12/27/192D 3D TSV
US10233188 433 221 HGNC:1771 HGNC:1773 CDK2/4/6 inhibitors Pfizer Inc. 12/27/192D 3D TSV
US10227357 1107 650 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 12/27/192D 3D TSV
US10231967 323 159 HGNC:620 Compounds and their use as BACE inhibitors AstraZeneca AB 12/27/192D 3D TSV
US10227360 50 49 HGNC:19061 Compounds for use as GPR120 agonists Piramal Enterprises Limited 12/27/192D 3D TSV
US10227329 268 130 HGNC:9967 Compounds useful for treating disorders related to RET BLUEPRINT MEDICINES CORPORATION 12/27/192D 3D TSV
US10227314 13 13 HGNC:2501 Cystathionine-gamma-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. 12/27/192D 3D TSV
US10227373 6 6 Enantiomers of the 1′,6′-isomer of neplanocin A Auburn University 12/27/192D 3D TSV
US10227334 8 8 HGNC:3467 Estrogen receptor modulators and uses thereof Genentech, Inc. 12/27/192D 3D TSV
US10233187 49 47 HGNC:7967 Fused bicyclic compounds for the treatment of disease AKARNA THERAPEUTICS, LTD. 12/27/192D 3D TSV
US10233189 78 76 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 12/27/192D 3D TSV
US10227310 6 6 HGNC:32311 Ghrelin 0-acyl transferase inhibitors Eli Lilly and Company 12/27/192D 3D TSV
US10227312 46 46 HGNC:12524 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. 12/27/192D 3D TSV
US10227342 400 99 HGNC:3236 Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. 12/27/192D 3D TSV
US10226449 595 337 HGNC:3594 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V Biosciences, Inc. 12/27/192D 3D TSV
US10231957 21 21 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 12/27/192D 3D TSV
US10233190 160 157 HGNC:6059 IDO inhibitors NEWLINK GENETICS CORPORATION 12/27/192D 3D TSV
US10227341 146 145 HGNC:1133 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. 12/27/192D 3D TSV
US10227327 27 11 Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety Universitetet | Oslo 12/27/192D 3D TSV
US10227343 112 109 HGNC:4596 Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 12/27/192D 3D TSV
US10233152 161 158 HGNC:29079 LSD1 inhibitors MIRATI THERAPEUTICS, INC. 12/27/192D 3D TSV
US10227331 1137 369 Metallo-β-lactamase inhibitors Merck Sharp & Dohme Corp. 12/27/192D 3D TSV
US10231963 109 39 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 12/27/192D 3D TSV
US10227346 104 104 HGNC:10260 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof Pfizer Inc. 12/27/192D 3D TSV
US10227350 167 129 HGNC:8980 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 12/27/192D 3D TSV
US10227336 32 16 HGNC:4849 HGNC:4848 Pyrazole orexin receptor antagonists Merck Sharp & Dohme Corp 12/27/192D 3D TSV
US10227295 48 24 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of The University of Illinois 12/27/192D 3D TSV
US10226464 150 75 HGNC:7794 Small molecule NF-κB inhibitors ImmuneTarget, Inc. 12/27/192D 3D TSV
US10233173 647 642 Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators JANSSEN PHARMACEUTICA NV 12/27/192D 3D TSV
US10227338 181 136 HGNC:10593 HGNC:10597 Substituted benzenesulfonamides as sodium channel blockers Daewoong Pharmaceutical Co., Ltd. 12/27/192D 3D TSV
US10233160 150 75 HGNC:391 HGNC:10436 Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors Merck Patent GmbH 12/27/192D 3D TSV
US10233182 245 244 HGNC:3357 Substituted spirocyclic inhibitors of autotaxin X-Rx, Inc. 12/27/192D 3D TSV
US10227332 8 4 HGNC:2160 T-type calcium channel modulator and uses thereof UTI LIMITED PARTNERSHIP; THE UNIVERSITY OF MONTANA 12/27/192D 3D TSV
US10233177 25 25 TRPV1 vanilloid receptor antagonists with a bicyclic portion TBA 12/27/192D 3D TSV
US10227340 27 26 HGNC:17967 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors Bristol-Myers Squibb Company 12/27/192D 3D TSV
US10227359 58 28 HGNC:13575 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 12/27/192D 3D TSV
US9872852 297 292 HGNC:17635 Compounds useful as immunomodulators Bristol-Myers Squibb Company 12/19/192D 3D TSV
US9873693 331 307 Methods of treatment using pyridinonyl PDK1 inhibitors Sunesis Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc. 12/19/192D 3D TSV
US9873683 43 43 HGNC:8535 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD; KYUSHU UNIVERSITY 12/19/192D 3D TSV
US9873709 1144 774 HGNC:6190 HGNC:6192 Triazolopyridine compounds, compositions and methods of use thereof Genentech, Inc. 12/19/192D 3D TSV
US9867826 100 47 HGNC:391 Heterocycles as modulators of kinase activity Merck Patent GmbH 12/12/192D 3D TSV
US9868726 123 72 HGNC:6307 HGNC:8804 HGNC:9437 Pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 12/12/192D 3D TSV
US9868720 93 92 HGNC:6851 C-linked heterocycloaklyl substituted pyrimidines and their uses Genentech, Inc. 12/10/192D 3D TSV
US9868738 102 51 HGNC:934 HGNC:933 Diazine-fused amidines as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 12/10/192D 3D TSV
US9868744 23 19 HGNC:3020 Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. 12/10/192D 3D TSV
US9868729 216 214 HGNC:11491 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. 12/10/192D 3D TSV
US9867833 197 185 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 12/10/192D 3D TSV
US9868748 113 110 HGNC:10260 Thiazolopyrrolidine inhibitors of ROR- γ Vitae Pharmaceuticals, Inc. 12/10/192D 3D TSV
US9862688 47 7 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:76 HGNC:12440 Hydrophobically tagged janus kinase inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. 12/03/192D 3D TSV
US9862730 405 393 HGNC:3540 Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Bristol-Myers Squibb Company; Universite De Montreal 12/03/192D 3D TSV
US9861612 9 7 HGNC:10260 Indolyl-containing RORγt inhibitors ORCA PHARMACEUTICALS LIMITED 12/03/192D 3D TSV
US9862726 40 20 HGNC:8154 HGNC:8156 Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans Purdue Pharma L.P. 12/03/192D 3D TSV
US9862679 189 58 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH 12/03/192D 3D TSV
US9862711 91 13 HGNC:8978 HGNC:8984 HGNC:8975 HGNC:3942 HGNC:8974 HGNC:8977 HGNC:8976 Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors NOVARTIS AG 12/03/192D 3D TSV
US9862721 13 13 HGNC:3357 Tetrahydrocarboline derivative ONO PHARMACEUTICAL CO., LTD. 12/03/192D 3D TSV
US9862707 103 83 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 12/03/192D 3D TSV
US9856252 107 106 HGNC:10894 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase Cancer Therapeutics CRC Pty Ltd 11/21/192D 3D TSV
US9855269 345 340 HGNC:6866 Aminoquinazoline and pyridopyrimidine derivatives Genentech, Inc. 11/21/192D 3D TSV
US9856239 42 38 HGNC:17989 Carboxylic acid compound, method for preparation thereof, and use thereof InventisBio Shanghai Ltd. 11/21/192D 3D TSV
US9856263 41 39 HGNC:3020 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. 11/21/192D 3D TSV
US9856220 125 124 HGNC:8772 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 11/21/192D 3D TSV
US9856257 68 68 HGNC:16672 Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) SANOFI 11/21/192D 3D TSV
US9856274 42 42 HGNC:8772 Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors Sunovion Pharmaceuticals Inc. 11/21/192D 3D TSV
US9856250 58 57 HGNC:1395 Substituted tropane derivatives TOA EIYO LTD. 11/21/192D 3D TSV
US9855229 11 11 HGNC:10260 Treatment of respiratory disorders using ROR-gamma inhibitors GLENMARK PHARMACEUTICALS S.A. 11/21/192D 3D TSV
US9849138 10 5 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties The Regents of the University of Michigan 11/14/192D 3D TSV
US9850203 128 122 HGNC:3357 Autotaxin inhibitor compounds PHARMAKEA, INC. 11/14/192D 3D TSV
US9850225 378 375 HGNC:17635 Compounds useful as immunomodulators Bristol-Myers Squibb Company 11/14/192D 3D TSV
US9845313 167 151 HGNC:10597 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED 11/14/192D 3D TSV
US9850245 24 21 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 11/14/192D 3D TSV
US9845310 772 485 HGNC:339 Intermediates for preparing triazole agonists of the APJ receptor AMGEN INC. 11/14/192D 3D TSV
US9845308 66 62 HGNC:10260 Isoindoline inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 11/14/192D 3D TSV
US9844553 19 10 HGNC:2592 HGNC:2591 Pyrazolopyridyl compounds as aldosterone synthase inhibitors Merck Sharp & Dohme Corp. 11/14/192D 3D TSV
US9844535 28 27 HGNC:6080 SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors Indiana University Research and Technology Corporation 11/14/192D 3D TSV
US9845333 164 47 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators TBA 11/14/192D 3D TSV
US9850258 152 43 HGNC:6192 HGNC:1133 Substituted tetrahydrocarbazole and carbazole carboxamide compounds Bristol-Myers Squibb Company 11/14/192D 3D TSV
US9850277 402 207 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. 11/14/192D 3D TSV
US9850257 26 13 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation; Incyte Holdings Corporation 11/14/192D 3D TSV
US9840503 33 10 HGNC:7027 HGNC:12446 Heterocyclic compounds and uses thereof Incyte Corporation 10/31/192D 3D TSV
US9840501 242 121 Morpholin-pyridine derivatives Hoffmann-La Roche Inc. 10/31/192D 3D TSV
US9840508 90 18 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders OGED SA 10/31/192D 3D TSV
US9840498 95 32 HGNC:8978 HGNC:8975 HGNC:8977 Substituted quinazolin-4-one derivatives Novartis AG 10/31/192D 3D TSV
US9834554 41 41 HGNC:1133 BTK inhibitors Merck Sharp & Dohme Corp. 10/28/192D 3D TSV
US9834513 249 125 HGNC:6371 HGNC:6357 Benzylamine derivatives Kalvista Pharmceuticals Limited 10/28/192D 3D TSV
US9834543 16 12 HGNC:10597 Indazoles and use thereof Purdue Pharma L.P. 10/28/192D 3D TSV
US9833448 14 14 HGNC:16709 Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp. 10/28/192D 3D TSV
US9834548 407 129 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyridazine compounds as JAK inhibitors Portola Pharmaceuticals, Inc. 10/28/192D 3D TSV
US9834551 220 109 HGNC:6193 HGNC:6171 Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors ARRIEN PHARMACEUTICALS LLC 10/28/192D 3D TSV
US9834564 209 209 HGNC:8772 Substituted quinolines as PDE-10 inhibitors Sunovion Pharmaceuticals Inc. 10/28/192D 3D TSV
US9833457 26 13 HGNC:8783 Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors vTv Therapeutics LLC 10/28/192D 3D TSV
US9834565 58 29 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 10/28/192D 3D TSV
US10221182 98 19 HGNC:4586 HGNC:6251 HGNC:2625 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED 10/27/192D 3D TSV
US10221172 65 64 HGNC:4596 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 10/27/192D 3D TSV
US10221173 451 159 HGNC:6251 HGNC:3467 Chemical compounds AstraZeneca AB 10/27/192D 3D TSV
US10221177 261 248 HGNC:497 Inhibiting the transient receptor potential A1 ion channel Hydra Biosciences, Inc. 10/27/192D 3D TSV
US10221163 1497 492 Metallo-beta-lactamase inhibitors Merck Sharp & Dohme Corp. 10/27/192D 3D TSV
US10221174 46 22 HGNC:6943 HGNC:990 N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10/27/192D 3D TSV
US10221197 528 147 HGNC:8978 HGNC:8980 HGNC:8977 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 10/27/192D 3D TSV
US10221178 83 82 HGNC:8977 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme Corp. 10/27/192D 3D TSV
US10221195 46 44 HGNC:438 Pyridine compounds Daiichi Sankyo Company, Limited; Sanford Burnham Prebys Medical Discovery Institute 10/27/192D 3D TSV
USRE47267 31 25 HGNC:6027 Pyridinecarboxamides as CXCR2 modulators Syntrix Biosystems, Inc. 10/27/192D 3D TSV
US10221175 42 42 HGNC:1950 Substituted pyrrolo[3,4-e]indolizines, imidazo[1,2-a]pyrrolo[3,4-e]pyridines, pyrrolo[3,4-e][1,2,4]triazolo[1,5-a]pyridines and pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyridines as positive allosteric modulators of muscarinic acetylcholine receptor M1 Vanderbilt University 10/27/192D 3D TSV
US9828368 146 64 HGNC:4849 Oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 10/24/192D 3D TSV
US9828396 92 92 HGNC:2771 Alkyne compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 10/22/192D 3D TSV
US9828348 10 10 HGNC:10597 Benzimidazole derivatives and use thereof Purdue Pharma L.P. 10/22/192D 3D TSV
US9828339 224 224 HGNC:1952 Biphenyl derivatives and methods for preparing same DONG-A ST CO., LTD 10/22/192D 3D TSV
US9828343 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 10/22/192D 3D TSV
US9828369 167 166 HGNC:16940 Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Merck Sharpe & Dohme Corp. 10/22/192D 3D TSV
US9828378 257 69 HGNC:8978 HGNC:8972 HGNC:8975 HGNC:8977 Kinase inhibitors and methods of use Intellikine LLC 10/22/192D 3D TSV
US9828374 94 47 Substituted pyrazino[2,2-a]isoquinoline derivatives Hoffmann-La Roche Inc. 10/22/192D 3D TSV
US9828381 88 88 Substituted pyrazolopyrimidines and method of use AbbVie Deutschland GmbH & Co. KG; AbbVie Inc. 10/22/192D 3D TSV
US10214477 210 56 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Oryzon Genomics S.A. 10/20/192D 3D TSV
US10214524 20 19 2-heteroaryl carboxamides BAYER INTELLECTUAL PROPERTY GMBH 10/20/192D 3D TSV
US10214516 14 14 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US10214478 11 11 Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof TBA 10/20/192D 3D TSV
US10214545 36 18 Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders BAYER PHARMA AKTIENGESELLSCHAFT 10/20/192D 3D TSV
US10214509 35 18 HGNC:10593 HGNC:10597 Amino-substituted heterocyclic derivatives as sodium channel inhibitors Almirall, S.A. 10/20/192D 3D TSV
US10214536 76 76 HGNC:11584 Amlexanox analogs THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10/20/192D 3D TSV
US9822124 255 85 HGNC:19310 HGNC:8987 Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors Incyte Corporation 10/20/192D 3D TSV
US10214537 824 774 HGNC:8977 Bicyclic heteroaryl amine compounds Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214528 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 10/20/192D 3D TSV
US10214546 213 174 HGNC:1133 Btk inhibitors Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214507 138 137 HGNC:8846 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Reset Therapeutics, Inc. 10/20/192D 3D TSV
US10220048 100 97 HGNC:9665 Compositions and methods for treating ocular diseases AERPIO THERAPEUTICS, INC. 10/20/192D 3D TSV
US10213407 9 9 Compounds and methods for inhibiting production of trimethylamine THE PROCTER & GAMBLE COMPANY; THE CLEVELAND CLINIC FOUNDATION 10/20/192D 3D TSV
US10220040 9 9 Compounds, compositions and methods useful for cholesterol mobilization Cerenis Therapeutics Holding SA 10/20/192D 3D TSV
US9822074 99 94 HGNC:7045 Dihydropyridinone MGAT2 inhibitors Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214512 386 227 HGNC:3529 HGNC:6357 Factor XIA inhibitors Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214492 511 238 HGNC:10924 HGNC:10922 Heterocyclic inhibitors of MCT4 Vettore, LLC 10/20/192D 3D TSV
US10214535 32 16 HGNC:4849 HGNC:4848 Hydroxmethyl piperidine orexin receptor antagonists Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214544 155 154 HGNC:3540 Imidazopyridazine and imidazothiadiazole compounds Universite De Montreal 10/20/192D 3D TSV
US9822068 26 13 HGNC:3553 Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments The Regents of the University of California; Fondazione Istituto Italiano di Technologia 10/20/192D 3D TSV
US10221129 293 288 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US9822103 94 92 HGNC:3527 Inhibitors of lysine methyl transferase Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10221161 192 94 HGNC:6371 HGNC:6357 Inhibitors of plasma kallikrein Kalvista Pharmaceuticals Limited 10/20/192D 3D TSV
US10221160 12 4 HGNC:2637 HGNC:2623 HGNC:2621 Metalloenzyme inhibitor compounds Mycovia Pharmaceuticals, Inc. 10/20/192D 3D TSV
US9820989 119 88 HGNC:6307 HGNC:8804 Method of treating conditions with kinase inhibitors ALLERGAN, INC. 10/20/192D 3D TSV
US10214533 23 7 HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders OGEDA SA 10/20/192D 3D TSV
US10213421 10 10 HGNC:1604 Pharmaceutical formulations comprising CCR3 antagonists Alkahest, Inc. 10/20/192D 3D TSV
US10214519 354 327 HGNC:8980 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 10/20/192D 3D TSV
US9822120 64 32 HGNC:1133 Protein kinase inhibitors Pharmascience Inc. 10/20/192D 3D TSV
US10214518 8 6 HGNC:9602 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. 10/20/192D 3D TSV
US10221156 6 6 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO.5) LIMITED 10/20/192D 3D TSV
US10214511 56 3 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3765 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1133 HGNC:1771 HGNC:6860 HGNC:11719 HGNC:7972 HGNC:1774 HGNC:6524 HGNC:1775 Quinazolines as potassium ion channel inhibitors Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10213433 373 370 HGNC:990 Solid dispersions containing an apoptosis-inducing agent AbbVie Inc. 10/20/192D 3D TSV
US10214534 44 44 Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10213416 11 11 HGNC:735 Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments The Regents of the University of Chicago; Fondazione Istituto Italiano di Technologia 10/20/192D 3D TSV
US10213427 107 107 HGNC:3690 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 Incyte Corporation; Incyte Holdings Corporation 10/20/192D 3D TSV
US9822102 357 143 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT 10/20/192D 3D TSV
US10221142 124 118 HGNC:10260 Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10214515 36 9 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Substituted pyrazoles as inhibitors of fibroblast growth factor receptor Zhejiang Hisun Pharmaceutical Co., Ltd. 10/20/192D 3D TSV
US10221146 424 411 HGNC:10260 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 10/20/192D 3D TSV
US10221162 788 507 HGNC:339 Triazole agonists of the APJ receptor AMGEN INC. 10/20/192D 3D TSV
US10214527 94 65 HGNC:7218 Triazolopyridine inhibitors of myeloperoxidase Bristol-Myers Squibb Company 10/20/192D 3D TSV
US10214530 118 57 HGNC:12008 HGNC:20692 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN 10/20/192D 3D TSV
US9815850 266 255 Compounds, compositions and methods Denali Therapeutics Inc. 10/14/192D 3D TSV
US9815836 74 33 HGNC:17967 Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof Merck Patent GmbH 10/14/192D 3D TSV
US9815840 24 24 HGNC:7029 Protein kinase inhibitor containing pyrrolopyridazine derivative The Asan Foundation 10/14/192D 3D TSV
US9815842 127 126 HGNC:6819 Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors Novartis AG 10/14/192D 3D TSV
US9815861 12 12 HGNC:7056 Selective glycosidase inhibitors and uses thereof Alectos Therapeutics, Inc.; Merck Sharp & Dohme Corp. 10/14/192D 3D TSV
US9815846 228 227 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 10/14/192D 3D TSV
US9815832 184 92 HGNC:8781 HGNC:8783 Azabenzimidazole compounds Pfizer Inc. 10/13/192D 3D TSV
US9815790 48 23 HGNC:2160 HGNC:2159 Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists Janssen Pharmaceutica NV 10/13/192D 3D TSV
US9815819 87 76 HGNC:2771 Complement pathway modulators and uses thereof NOVARTIS AG 10/13/192D 3D TSV
US9814715 14 7 HGNC:7966 HGNC:7965 Liver X receptor modulators Vitae Pharamceuticals, Inc. 10/13/192D 3D TSV
US9815796 1267 689 HGNC:8777 Pyrimidone carboxamide compounds as PDE2 inhibitors Merck Sharp & Dohme Corp.; MSD R & D (China) Co. LTD. 10/13/192D 3D TSV
US9815834 91 91 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. 10/13/192D 3D TSV
US9815820 30 7 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 10/13/192D 3D TSV
US9814704 167 166 HGNC:6850 Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors The University of Rochester 10/13/192D 3D TSV
US9809582 68 24 HGNC:8781 HGNC:1952 Aminoester derivatives CHIESI FARMACEUTICI S.p.A. 10/07/192D 3D TSV
US9809568 7 7 HGNC:18618 Compounds inhibiting leucine-rich repeat kinase enzyme activity Merck Sharp & Dohme Corp. 10/07/192D 3D TSV
US9809572 16 1 HGNC:427 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds Suzhou Zelgen Biopharmaceuticals Co., Ltd. 10/07/192D 3D TSV
US9808445 32 30 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme Corp.; Mochida Pharmaceutical Co., Ltd. 10/07/192D 3D TSV
US9809545 25 25 HGNC:3551 Factor XIa inhibitors Merck Sharp & Dohme Corp. 10/07/192D 3D TSV
US9809574 248 248 HGNC:990 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 10/07/192D 3D TSV
US9809583 31 31 Oxazolidine-based compound and selective androgen receptor agonist comprising same DONG-A ST CO., LTD. 10/07/192D 3D TSV
US9809561 424 422 HGNC:10260 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease MERCK SHARP & DOHME CORP.; LYCERA CORPORATION 10/07/192D 3D TSV
US9802907 47 44 HGNC:12805 2-aryl selenazole compound and pharmaceutical composition thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. 10/01/192D 3D TSV
US9802947 18 9 HGNC:2536 HGNC:2545 3-oxo-tetrahydro-furo[3,2-b]pyrrol-4(5H)-yl) derivatives II GRÜNENTHAL GMBH 10/01/192D 3D TSV
US9802924 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 10/01/192D 3D TSV
US9802944 68 34 HGNC:10555 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffmann-La Roche Inc. 10/01/192D 3D TSV
US9801889 200 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 10/01/192D 3D TSV
US9802928 48 24 HGNC:934 HGNC:933 C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 10/01/192D 3D TSV
US9802960 484 476 HGNC:8974 Heteroaryls and uses thereof Millennium Pharmaceuticals, Inc. 10/01/192D 3D TSV
US9802945 23 23 HGNC:4076 Imidazopyridazine derivatives as modulators of the GABAA receptor activity Pfizer Limited 10/01/192D 3D TSV
US9802915 262 215 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Company 10/01/192D 3D TSV
US9802920 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffman-La Roche Inc.; Chugai Pharamceutical Co. 10/01/192D 3D TSV
US9802904 64 62 Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof The United States of America, as represented by the Secretary, Department of Health and Human Services; University of Delaware 10/01/192D 3D TSV
US9802939 77 77 HGNC:3529 Macrocycles as factor XIa inhibitors Bristol-Myers Squibb Company 10/01/192D 3D TSV
US9802918 324 107 HGNC:19310 HGNC:8987 Pyridineamine compounds useful as Pim kinase inhibitors Incyte Corporation 10/01/192D 3D TSV
US9801872 35 34 HGNC:1133 Pyridinyl and fused pyridinyl triazolone derivatives Takeda Pharmaceutical Company Limited 10/01/192D 3D TSV
US9801888 129 129 HGNC:3942 Pyrimidine compounds as mTOR and PI3K inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY 10/01/192D 3D TSV
US9801878 34 32 HGNC:8772 Quinoline derivatives as PDE10A enzyme inhibitors H. Lundbeck A/S 10/01/192D 3D TSV
US9796719 321 219 HGNC:3357 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 09/24/192D 3D TSV
US9796741 168 167 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796664 27 11 HGNC:4852 HGNC:4854 HGNC:4853 Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors BIOMARIN PHARMACEUTICAL INC. 09/23/192D 3D TSV
US9796729 36 33 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC 09/23/192D 3D TSV
US9796710 47 44 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796702 52 23 HGNC:2592 HGNC:2591 Dihydroquinoline pyrazolyl compounds Hoffmann-La Roche Inc. 09/23/192D 3D TSV
US9796700 349 344 HGNC:6877 ERK inhibitors and uses thereof Celgene CAR LLC 09/23/192D 3D TSV
US9796680 41 31 HGNC:4177 Glucocerebrosidase modulators and uses thereof Alectos Therapeutics Inc. 09/23/192D 3D TSV
US9796720 31 31 HGNC:7978 Imidazole-derived modulators of the glucocorticoid receptor Bristol-Myers Squibb Company 09/23/192D 3D TSV
US9796706 505 173 HGNC:6881 HGNC:6872 HGNC:6886 Inhibitors of Jun N-terminal kinase IMAGO PHARMACEUTICALS, INC. 09/23/192D 3D TSV
US9796672 170 93 HGNC:8157 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. 09/23/192D 3D TSV
US9796742 135 61 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/23/192D 3D TSV
US9795611 60 59 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma, Inc. 09/23/192D 3D TSV
US9796723 60 60 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma, Inc. 09/23/192D 3D TSV
US9796707 36 36 HGNC:11305 Piperazine derivatives for treating disorders The University of Nottingham; NewSouth Innovations PTY Limited 09/23/192D 3D TSV
US9795602 9 9 HGNC:9213 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use GILEAD SCIENCES, INC. 09/23/192D 3D TSV
US9795608 15 15 HGNC:1133 Protein kinase inhibitors PHARMASCIENCE, INC. 09/23/192D 3D TSV
US9796725 125 122 HGNC:30661 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 09/23/192D 3D TSV
US9796732 42 42 HGNC:3942 Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. 09/23/192D 3D TSV
US9796708 1363 1352 HGNC:1780 Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors AbbVie Inc. 09/23/192D 3D TSV
US9795606 35 35 HGNC:7027 Pyrrolopyrimidine compounds for the treatment of cancer The University of North Carolina at Chapel Hill 09/23/192D 3D TSV
US9796687 18 18 HGNC:8791 S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS 09/23/192D 3D TSV
US9796716 127 124 HGNC:1133 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. 09/23/192D 3D TSV
US9796724 517 232 HGNC:8031 HGNC:12440 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma, Inc. 09/23/192D 3D TSV
US9796704 1540 275 HGNC:3763 HGNC:3430 HGNC:6307 HGNC:3386 HGNC:3395 HGNC:3236 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. 09/23/192D 3D TSV
US10208016 23 23 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED 09/21/192D 3D TSV
US10208024 246 83 HGNC:3690 HGNC:3689 HGNC:3688 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases Array BioPharma Inc. 09/21/192D 3D TSV
US10208044 3 3 HGNC:85 ACC inhibitors and uses thereof GILEAD APOLLO, LLC 09/21/192D 3D TSV
US10208011 50 25 HGNC:4485 Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. 09/21/192D 3D TSV
US10208081 137 133 HGNC:7967 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Enanta Pharmaceuticals, Inc. 09/21/192D 3D TSV
US10206907 633 322 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV 09/21/192D 3D TSV
US10208056 240 97 HGNC:19682 HGNC:1779 Condensed tricyclic compounds as protein kinase inhibitors FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO) 09/21/192D 3D TSV
US10208000 19 19 Eis inhibitors University of Kentucky Research Foundation 09/21/192D 3D TSV
US10208040 34 11 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC 09/21/192D 3D TSV
US10208019 434 246 HGNC:4324 GLP-1 receptor agonists and uses thereof Pfizer Inc. 09/21/192D 3D TSV
US10208023 23 7 HGNC:10597 Heterocyclic inhibitors of the sodium channel TBA 09/21/192D 3D TSV
US10208039 147 146 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 09/21/192D 3D TSV
US10208066 156 68 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED 09/21/192D 3D TSV
US10208060 10 10 HGNC:1232 Inhibitors of HIF prolyl hydroxylase Merck Sharp & Dohme Corp. 09/21/192D 3D TSV
US10207999 226 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. 09/21/192D 3D TSV
US10208064 36 36 HGNC:6255 Inhibitors of the renal outer medullary potassium channel WuXi AppTec (Shanghai) Co Ltd 09/21/192D 3D TSV
US10207991 170 93 HGNC:8157 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. 09/21/192D 3D TSV
US10208068 46 46 HGNC:3529 Macrocycles as factor XIa inhibitors Bristol-Myers Squibb Company 09/21/192D 3D TSV
US10208043 31 31 Methods for inhibiting fascin Cornell University; Novita Pharmaceuticals, Inc. 09/21/192D 3D TSV
US10208027 4 1 HGNC:882 Processes for preparing ATR inhibitors Vertex Pharmaceuticals Incorporated 09/21/192D 3D TSV
US10208020 126 62 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics S.A. 09/21/192D 3D TSV
US10208021 21 21 HGNC:3529 Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors Bristol-Myers Squibb Company 09/21/192D 3D TSV
US10208047 36 35 HGNC:1133 Tertiary alcohol imidazopyrazine BTK inhibitors Merck Sharp & Dohme Corp. 09/21/192D 3D TSV
US10206931 611 311 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/21/192D 3D TSV
US10208071 189 187 HGNC:3827 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases ALLERGAN, INC. 09/21/192D 3D TSV
US9789094 21 21 HGNC:6059 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Incyte Holdings Corporation; Incyte Corporation 09/09/192D 3D TSV
US9790230 212 106 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives Hoffmann-La Roche Inc. 09/09/192D 3D TSV
US9790229 360 356 HGNC:1133 Bruton's tyrosine kinase inhibitors Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. 09/09/192D 3D TSV
US9790233 21 19 HGNC:5154 Compositions and methods of modulating 15-PGDH activity Case Western Reserve University; Board of Regents of the University of Texas System; University of Kentucky Research Foundation 09/09/192D 3D TSV
US9789116 96 91 HGNC:5154 Compositions and methods of modulating short-chain dehydrogenase activity Case Western Reserve University; Board of Regents of the University of Texas System 09/09/192D 3D TSV
US9789100 132 45 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 09/09/192D 3D TSV
US9789110 55 55 HGNC:16940 Diacylglycerol acyltransferase 2 inhibitors Pfizer Inc. 09/09/192D 3D TSV
US9790212 110 72 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED 09/09/192D 3D TSV
US9790221 574 287 HGNC:17967 Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH 09/09/192D 3D TSV
US9790228 640 194 HGNC:8979 HGNC:8978 HGNC:8972 HGNC:8977 Heterocyclic kinase inhibitors Intellikine LLC 09/09/192D 3D TSV
US9790203 25 25 HGNC:8772 Inhibitor compounds of phosphodiesterase type 10A ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG 09/09/192D 3D TSV
US9790174 318 118 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/09/192D 3D TSV
US9790209 47 17 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 09/09/192D 3D TSV
US9790196 12 4 HGNC:6833 HGNC:6834 HGNC:29079 Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae ORYZON GENOMICS S.A. 09/09/192D 3D TSV
US9790235 133 130 HGNC:6887 MK2 inhibitors and uses thereof Celgene CAR LLC 09/09/192D 3D TSV
US9791447 30 10 HGNC:17927 HGNC:30402 HGNC:23116 Methods of identifying SENP1 inhibitors City of Hope 09/09/192D 3D TSV
US9790201 119 113 Piperidine and azepine derivatives as prokineticin receptor modulators Takeda Pharmaceutical Company Limited 09/09/192D 3D TSV
US9790180 126 41 HGNC:4852 HGNC:4854 HGNC:4853 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC 09/09/192D 3D TSV
US9790217 174 85 HGNC:2592 HGNC:2591 Pyridinyloxy- and phenyloxy-pyrazolyl compounds Hoffmann-La Roche Inc. 09/09/192D 3D TSV
US9789082 100 20 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 09/09/192D 3D TSV
US9790198 102 98 HGNC:4498 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes Janssen Pharmaceutica NV 09/09/192D 3D TSV
US9790220 49 25 HGNC:4849 HGNC:4848 Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists Takeda Pharmaceutical Company Limited 09/09/192D 3D TSV
US9790158 24 12 HGNC:14063 HGNC:13315 Substituted tropolone derivatives and methods of use UNIVERSITY OF CONNECTICUT 09/09/192D 3D TSV
US10202412 19 16 β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections Atea Pharmaceuticals, Inc. 09/02/192D 3D TSV
US10202369 883 393 HGNC:2596 HGNC:2637 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 1,3-thiazol-2-yl substituted benzamides Bayer Aktiengesellschaft 09/02/192D 3D TSV
US10202365 79 39 HGNC:9967 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors BLUEPRINT MEDICINES CORPORATION 09/02/192D 3D TSV
US10202411 20 15 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV IDENIX PHARMACEUTICALS LLC 09/02/192D 3D TSV
US10202377 207 115 HGNC:11772 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof Samumed, LLC 09/02/192D 3D TSV
US10202383 46 46 HGNC:3009 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Boehringer Ingelheim International GmbH 09/02/192D 3D TSV
US10202370 154 153 HGNC:6342 Benzimidazole derivatives as selective proteine kinase inhibitors AB SCIENCE 09/02/192D 3D TSV
US10202368 88 88 HGNC:23692 CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. 09/02/192D 3D TSV
US10202399 34 34 HGNC:2671 Dihydroxy aromatic heterocyclic compound Takeda Pharmaceutical Company Limited 09/02/192D 3D TSV
US10202388 53 43 HGNC:11708 HGNC:6059 Fused-ring compounds, pharmaceutical composition and uses thereof SHANGHAI DE NOVO PHARMATECH CO., LTD. 09/02/192D 3D TSV
US10202390 29 28 HGNC:6266 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Company 09/02/192D 3D TSV
US10202373 49 49 HGNC:8974 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US10202367 71 62 Heterocyclic compounds and methods of use thereof The United States of America, as represented by the Secretary, Department of Health and Human Services; University of Kansas 09/02/192D 3D TSV
US10202381 147 145 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 09/02/192D 3D TSV
US10202418 29 20 HGNC:9958 HGNC:2529 Hydroxy-ethylene derivatives for the treatment of arthrosis MERCK PATENT GMBH 09/02/192D 3D TSV
US10202362 4 2 HGNC:2528 HGNC:6710 Inhibitors of leukotriene A4 hydrolase Celtaxsys, Inc. 09/02/192D 3D TSV
US10202350 187 81 HGNC:10924 HGNC:23357 MCT4 inhibitors for treating disease Vettore, LLC 09/02/192D 3D TSV
US10202403 19 18 Macrocyclic benzofuran compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 09/02/192D 3D TSV
US10202375 36 26 N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors Redx Pharma PLC 09/02/192D 3D TSV
US10202371 151 19 HGNC:8978 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors Novartis AG 09/02/192D 3D TSV
US10202404 128 127 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. 09/02/192D 3D TSV
US10202389 125 120 HGNC:12469 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 09/02/192D 3D TSV
US10202379 784 388 HGNC:11535 Substituted polycyclic carbamoyl pyridone derivative prodrug SHIONOGI & CO., LTD. 09/02/192D 3D TSV
US10202360 382 361 HGNC:2348 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. 09/02/192D 3D TSV
US10202354 120 120 HGNC:13610 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US10202378 434 200 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 09/02/192D 3D TSV
US9783488 107 107 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 08/20/192D 3D TSV
US9783501 80 80 HGNC:10582 Substituted quinolines as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 08/20/192D 3D TSV
US9783543 38 19 HGNC:7110 Aminoimidazopyridazines BAYER PHARMA AKTIENGESELLSCHAFT 08/19/192D 3D TSV
US9783530 84 40 HGNC:3529 HGNC:6357 Factor Xla inhibitors Merck Sharp & Dohme Corp. 08/19/192D 3D TSV
US9783573 132 66 HGNC:592 IAP antagonists Bristol-Myers Squibb Company 08/19/192D 3D TSV
US9783527 470 356 HGNC:10582 HGNC:10597 Indazole ureas and method of use AbbVie Inc. 08/19/192D 3D TSV
US9783556 68 22 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Respivert Limited; Topivert Pharma Limited 08/19/192D 3D TSV
US9783524 48 10 HGNC:427 HGNC:3236 Protein tyrosine kinase modulators and methods of use BETTA PHARMACEUTICALS CO., LTD. 08/19/192D 3D TSV
US9783551 11 9 HGNC:9642 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Glaceum Inc. 08/19/192D 3D TSV
US9783511 263 255 HGNC:10260 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 08/18/192D 3D TSV
US9783500 109 18 HGNC:7872 HGNC:7873 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition Northwestern University 08/17/192D 3D TSV
US9783499 24 24 HGNC:7029 Quinoline derivatives and their applications Shenyang Pharmaceutical University 08/17/192D 3D TSV
US9782415 530 232 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma, Inc. 08/17/192D 3D TSV
US9777004 61 33 Amino-substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH 08/13/192D 3D TSV
US9777020 185 185 HGNC:8031 Furo-3-carboxamide derivatives and methods of use AbbVie Inc. 08/13/192D 3D TSV
US9777008 310 306 HGNC:29652 PRMT5 inhibitors and uses thereof Epizyme, Inc. 08/13/192D 3D TSV
US9777010 124 111 HGNC:9922 Substituted 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 08/13/192D 3D TSV
US9777017 196 90 HGNC:6190 HGNC:6192 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Holdings Corporation; Incyte Corporation 08/13/192D 3D TSV
US9776995 524 366 HGNC:10593 HGNC:10597 Bicyclic sulfonamide compounds as sodium channel inhibitors Amgen Inc. 08/12/192D 3D TSV
US9776990 146 73 HGNC:13575 Isoindolone derivatives AbbVie Inc. 08/12/192D 3D TSV
US9777000 173 158 HGNC:8772 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. 08/12/192D 3D TSV
US9776991 211 206 HGNC:3402 Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase SANOFI 08/12/192D 3D TSV
US9777003 544 269 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 08/12/192D 3D TSV
US9775839 42 41 HGNC:11491 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors Merck Sharp & Dohme Corp. 08/11/192D 3D TSV
US9775844 440 109 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 08/11/192D 3D TSV
US9776974 122 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 08/11/192D 3D TSV
US9776988 32 8 HGNC:6307 HGNC:3690 HGNC:3689 HGNC:3688 Pyrazolylbenzo[d]imidazole derivatives Celon Pharma S.A. 08/11/192D 3D TSV
US9771369 502 253 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 08/06/192D 3D TSV
US9771375 159 156 HGNC:6315 Indazole compounds useful as ketohexokinase inhibitors Janssen Pharmaceutica NV 08/06/192D 3D TSV
US9771353 39 14 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 Kinase inhibitors based upon N-alkyl pyrazoles TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED 08/06/192D 3D TSV
US9771379 28 28 HGNC:933 N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides PFIZER INC. 08/06/192D 3D TSV
US9771376 56 51 HGNC:10593 HGNC:10597 N-substituted benzamides and methods of use thereof GENENTECH, INC.; XENON PHARMACEUTICALS INC. 08/06/192D 3D TSV
US9771359 37 33 HGNC:12716 Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II Medifron DBT Inc. 08/06/192D 3D TSV
US9771366 28 20 HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors PHOENIX MOLECULAR DESIGN 08/06/192D 3D TSV
US9771320 334 293 HGNC:10260 Carbocyclic sulfone RORγ modulators Bristol-Myers Squibb Company 08/05/192D 3D TSV
US9771329 122 119 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 08/05/192D 3D TSV
US9771316 35 17 HGNC:11063 Phenoxyalkylamine compound Osaka University; KNC Laboratories Co., Ltd. 08/02/192D 3D TSV
US9763922 595 308 HGNC:13575 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 07/30/192D 3D TSV
US9765057 34 14 HGNC:4849 HGNC:4848 3-ester-4 substituted orexin receptor antagonists Merck Sharp & Dohme Corp. 07/29/192D 3D TSV
US9765037 344 136 HGNC:4840 HGNC:11283 HGNC:76 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases University of Washington Through its Center for Commercialization 07/29/192D 3D TSV
US9765038 62 23 HGNC:3236 Heteroaryl compounds and uses thereof Celgene CAR LLC 07/29/192D 3D TSV
US9765054 75 74 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 07/29/192D 3D TSV
US9765056 173 173 HGNC:990 Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 07/29/192D 3D TSV
US9765068 193 193 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 07/29/192D 3D TSV
US9765060 118 113 HGNC:8977 Phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. 07/29/192D 3D TSV
US9765029 40 37 HGNC:10597 Pyridine compounds as sodium channel blockers Purdue Pharma L.P. 07/29/192D 3D TSV
US9765058 20 19 HGNC:1148 Substituted benzylpyrazoles Bayer Pharma Aktiengesellschaft 07/29/192D 3D TSV
US9765070 81 39 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 07/29/192D 3D TSV
US9765040 15 15 Therapeutic agent for pain Astellas Pharma Inc. 07/29/192D 3D TSV
US9765092 444 442 HGNC:12008 Tricyclic piperidine compounds ACTELION PHARMACEUTICALS LTD 07/29/192D 3D TSV
US9763957 206 201 HGNC:10548 Autotaxin inhibitors Novartis AG 07/26/192D 3D TSV
US9763952 568 263 HGNC:8975 HGNC:8977 Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives NOVARTIS AG 07/26/192D 3D TSV
US9765018 65 65 HGNC:6059 IDO inhibitors Bristol-Myers Squibb Company; Syngene International Limited; Bristol-Myers Squibb Company 07/26/192D 3D TSV
US9763943 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 07/26/192D 3D TSV
US9758480 44 44 HGNC:3529 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 07/22/192D 3D TSV
US9758508 11 11 HGNC:1133 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same CrystalGenomics, Inc. 07/22/192D 3D TSV
US9758505 35 35 HGNC:11708 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use iTeos Therapeutics 07/22/192D 3D TSV
US9758524 664 132 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors Merck Sharp & Dohme B.V. 07/22/192D 3D TSV
US10202344 88 67 HGNC:10597 Aryl substituted indoles and the use thereof Purdue Pharma L.P. 07/22/192D 3D TSV
US10201527 144 95 HGNC:4852 HGNC:4774 HGNC:13315 Benzimidazole derivatives: preparation and pharmaceutical applications MEI PHARMA, INC. 07/22/192D 3D TSV
US9758537 116 116 HGNC:2771 Compounds for treatment of complement mediated disorders Achillion Pharmaceuticals 07/22/192D 3D TSV
US9757383 30 15 HGNC:286 HGNC:1952 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities Almirall, S.A. 07/22/192D 3D TSV
US10202340 49 17 HGNC:12524 Glucosylceramide synthase inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN 07/22/192D 3D TSV
US9758495 7 7 Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer Amgen Inc. 07/22/192D 3D TSV
US9757369 28 27 HGNC:4617 Heterocyclic GSK-3 allosteric modulators Consejo Superior de Investigaciones Cientificas (CSIC) 07/22/192D 3D TSV
US9758517 21 21 HGNC:17071 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 07/22/192D 3D TSV
US10202330 54 18 HGNC:6833 HGNC:6834 HGNC:29079 Lysine specific demethylase-1 inhibitors and their use ORYZON GENOMICS, SA 07/22/192D 3D TSV
US9757364 370 71 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD 07/22/192D 3D TSV
US9758483 160 159 HGNC:10582 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 07/22/192D 3D TSV
US9758538 157 153 HGNC:8979 Pyrimidine derivatives PFIZER INC. 07/22/192D 3D TSV
US10201546 769 362 HGNC:10260 Quinolinyl modulators of RORγt Janssen Pharmaceutica NV 07/22/192D 3D TSV
US10201545 102 102 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. 07/22/192D 3D TSV
US10202339 353 350 Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. 07/22/192D 3D TSV
US9758523 20 20 HGNC:29079 Triazolopyridines and triazolopyrazines as LSD1 inhibitors Incyte Corporation 07/22/192D 3D TSV
US9751886 33 10 HGNC:934 HGNC:933 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) Janssen Pharmaceutica NV 07/11/192D 3D TSV
US9751873 161 138 HGNC:10260 Aryl sultam derivatives as RORc modulators Genentech, Inc. 07/11/192D 3D TSV
US9751885 801 224 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 07/11/192D 3D TSV
US9751856 6 6 Ethynyl derivatives HOFFMANN-LA ROCHE INC. 07/11/192D 3D TSV
US9751854 484 477 HGNC:8974 Heteroaryls and uses thereof Millennium Pharmaceuticals, Inc. 07/11/192D 3D TSV
US9751888 236 58 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 07/11/192D 3D TSV
US9751881 118 115 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 07/11/192D 3D TSV
US9751837 187 70 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED 07/11/192D 3D TSV
US9750744 68 47 HGNC:8031 Macrocyclic compounds as Trk kinase inhibitors Array BioPharma, Inc. 07/11/192D 3D TSV
US9750748 14 14 HGNC:2671 Pyridazinones as DAAO enzyme inhibitors Takeda Pharmaceutical Company Limited 07/11/192D 3D TSV
US9751832 42 21 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute, Inc.; Board of Trustees of the University of Illinois 07/11/192D 3D TSV
US9751843 148 148 HGNC:2097 Substituted uracils and use thereof Bayer Pharma Aktiengesellschaft 07/11/192D 3D TSV
US9751850 11 11 HGNC:497 TRPA1 antagonists ABBVIE INC. 07/11/192D 3D TSV
US9744173 132 114 HGNC:933 HGNC:2625 2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides Pfizer Inc. 07/05/192D 3D TSV
US9745284 120 59 HGNC:4849 HGNC:4848 2-pyridyloxy-4-ether orexin receptor antagonists Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745265 128 126 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745289 262 62 HGNC:2592 HGNC:2591 Aldosterone synthase inhibitors Boehringer Ingelheim International GmbH 07/05/192D 3D TSV
US9745304 64 32 Amidoimidazopyridazines as MKNK-1 kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 07/05/192D 3D TSV
US9744252 20 20 HGNC:6138 Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi PIRAMAL IMAGING SA 07/05/192D 3D TSV
US9745307 46 45 HGNC:6871 Compounds that are ERK inhibitors Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745328 898 885 HGNC:3650 Flap modulators Janssen Pharmaceutica NV 07/05/192D 3D TSV
US9745321 142 140 HGNC:8977 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD 07/05/192D 3D TSV
US9745317 28 23 HGNC:3020 Heterocyclic compounds and their use as dopamine D1 ligands Pfizer Inc. 07/05/192D 3D TSV
US9745310 199 198 HGNC:4597 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. 07/05/192D 3D TSV
US9745324 83 44 HGNC:934 HGNC:933 Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 07/05/192D 3D TSV
US9745282 100 47 HGNC:2592 HGNC:2591 Indoline compounds as aldosterone synthase inhibitors Merck Sharp & Dohme Corp; ElexoPharm GmbH 07/05/192D 3D TSV
US9744148 96 90 HGNC:6368 Kallikrein 7 inhibitors SIXERA Pharma AB 07/05/192D 3D TSV
US9745291 277 274 HGNC:29652 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. 07/05/192D 3D TSV
US9744172 287 286 HGNC:7027 Pyrazolopyrimidine compounds for the treatment of cancer The University of North Carolina at Chapel Hill 07/05/192D 3D TSV
US9745287 36 22 HGNC:10597 Pyrimidines and use thereof Purdue Pharma L.P. 07/05/192D 3D TSV
US9745311 266 89 HGNC:3690 HGNC:3689 HGNC:3688 Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors Incyte Corporation; Incyte Holdings Corporation 07/05/192D 3D TSV
US9745283 328 169 HGNC:7029 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. 07/05/192D 3D TSV
US9738626 7 7 HGNC:9595 Antagonists of prostaglandin EP3 receptor Pfizer Inc. 07/01/192D 3D TSV
US9737516 44 18 Bicyclic heterocycles as bet protein inhibitors Incyte Corporation 07/01/192D 3D TSV
US9738641 20 10 HGNC:6371 HGNC:6357 Bicyclic inhibitors Kalvista Pharmaceuticals Limited 07/01/192D 3D TSV
US9737544 120 24 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Compounds ASTEX THERAPEUTICS LIMITED 07/01/192D 3D TSV
US9738658 36 36 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors GlaxoSmithKline LLC 07/01/192D 3D TSV
US9738637 297 93 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quantical Research, Inc. 07/01/192D 3D TSV
US9738630 17 16 HGNC:3527 Inhibitors of lysine methyl transferase Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9737522 17 17 NMDA receptor modulators and uses related thereto Emory University 07/01/192D 3D TSV
US9738632 20 18 HGNC:7978 Phenyl and benzodioxinyl substituted indazoles derivatives AstraZeneca AB; Bayer Pharma Aktiengesellschaft 07/01/192D 3D TSV
US9738668 30 9 Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease University of Kansas 07/01/192D 3D TSV
US9737542 111 111 HGNC:19679 Pyrrolotriazine kinase inhibitors Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9738676 7 7 HGNC:8780 Selected macrolides with PDE4-inhibiting activity BASILEA PHARMACEUTICA AG 07/01/192D 3D TSV
US9737525 20 17 HGNC:10886 Small molecule activators of NRF2 pathway The General Hospital Corporation; The Regents of the University of California 07/01/192D 3D TSV
US9738628 36 21 Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions University of Utah Research Foundation 07/01/192D 3D TSV
US9738640 16 8 HGNC:6833 HGNC:6834 Substituted benzamide derivatives as in vitro MAO-B inhibitors “NTZ LAB” LTD. 07/01/192D 3D TSV
US9738649 771 379 HGNC:12716 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. 07/01/192D 3D TSV
US9738655 635 318 HGNC:6371 HGNC:3529 Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors Bristol-Myers Squibb Company 07/01/192D 3D TSV
US9730929 33 33 HGNC:7110 Substituted aminoimidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH 06/26/192D 3D TSV
US9732104 43 43 HGNC:2771 Ether compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/24/192D 3D TSV
US9732037 63 21 HGNC:7872 HGNC:7873 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors Northwestern University 06/23/192D 3D TSV
US9732060 560 555 HGNC:8534 Aminotriazine derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 06/23/192D 3D TSV
US9732094 901 326 HGNC:6251 HGNC:9413 Arylquinazolines Merck Patent GmbH 06/23/192D 3D TSV
US9732075 1982 990 HGNC:4849 HGNC:4848 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD 06/23/192D 3D TSV
US9732088 116 39 HGNC:934 HGNC:2529 HGNC:933 C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 06/23/192D 3D TSV
US9732103 16 16 HGNC:2771 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/23/192D 3D TSV
US9732061 76 38 HGNC:2160 HGNC:2159 Cinnoline derivatives useful as CB-1 receptor inverse agonists Janssen Pharmaceutica NV 06/23/192D 3D TSV
US9732087 30 30 HGNC:17383 Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. 06/23/192D 3D TSV
US9732093 691 353 HGNC:3650 FLAP modulators JANSSEN PHARMACEUTICA NV 06/23/192D 3D TSV
US9732066 239 237 HGNC:9599 Heterocyclic derivative and pharmaceutical drug NIPPON SHINY AKU CO., LTD. 06/23/192D 3D TSV
US9730939 366 326 HGNC:8977 Heterocyclylamines as PI3K inhibitors Incyte Holdings Corporation; Incyte Corporation 06/23/192D 3D TSV
US9732063 194 72 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 Kinase inhibitors RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED 06/23/192D 3D TSV
US9732044 8 8 HGNC:644 N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use GALDERMA RESEARCH & DEVELOPMENT 06/23/192D 3D TSV
US9732072 30 29 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 06/23/192D 3D TSV
US9732097 26 26 HGNC:6190 Process for the synthesis of a phosphoinositide 3-kinase inhibitor Incyte Corporation 06/23/192D 3D TSV
US9730940 387 370 HGNC:8977 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme 06/23/192D 3D TSV
US9732085 36 33 HGNC:3529 Pyridinone and pyrimidinone derivatives as factor Xia ONO PHARMACEUTICAL CO., LTD. 06/23/192D 3D TSV
US9730931 144 67 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine FGFR4 inhibitors EISAI R&D Management Co., Ltd. 06/23/192D 3D TSV
US9730934 33 11 HGNC:3432 HGNC:3430 HGNC:3236 Quinazoline derivatives substituted by aniline, preparation method and use thereof XUANZHU PHARMA CO., LTD. 06/23/192D 3D TSV
US9730937 1155 377 HGNC:9829 HGNC:1097 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION 06/23/192D 3D TSV
US9732092 23 23 HGNC:10966 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections Gilead Sciences, Inc. 06/23/192D 3D TSV
US10196387 88 87 HGNC:13575 Carbazole compounds useful as bromodomain inhibitors Bristol-Myers Squibb Company 06/16/192D 3D TSV
US10196396 240 174 HGNC:268 HGNC:262 HGNC:263 Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof HANDOK INC. 06/16/192D 3D TSV
US10196436 116 57 HGNC:3691 HGNC:3688 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 06/16/192D 3D TSV
US10196393 56 6 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC 06/16/192D 3D TSV
US10196404 3 1 HGNC:6943 MCL-1 inhibitors and methods of use thereof AstraZeneca AB 06/16/192D 3D TSV
US10196390 466 233 HGNC:6192 HGNC:12440 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 06/16/192D 3D TSV
US10196391 120 119 Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection Hoffmann-La Roche Inc. 06/16/192D 3D TSV
US10196374 50 24 HGNC:7978 HGNC:11892 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators AstraZeneca AB 06/14/192D 3D TSV
US10196354 127 127 HGNC:10260 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 06/14/192D 3D TSV
US10196381 41 41 HGNC:270 Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD 06/14/192D 3D TSV
US10196353 10 10 HGNC:8910 Chemical compounds GlaxoSmithKline Intellectual Property (No 2) Limited 06/14/192D 3D TSV
US10196378 44 9 HGNC:11283 HGNC:76 Inhibitors of BCR-ABL mutants and use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN 06/14/192D 3D TSV
US10196365 22 11 HGNC:3430 HGNC:3236 Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof ARROMAX PHARMATECH CO., LTD. 06/14/192D 3D TSV
US10196369 103 102 HGNC:3128 Spirocyclic EBI2 modulators SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 06/14/192D 3D TSV
US10196373 93 86 HGNC:11364 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 06/14/192D 3D TSV
US10196383 8 4 HGNC:4849 HGNC:4848 Substituted quinazoline compounds and preparation and uses thereof SUNSHINE LAKE PHARMA CO., LTD. 06/14/192D 3D TSV
US10196385 3 3 HGNC:20088 Tetrahydropyranyl benzamide derivatives Eli Lilly and Company 06/14/192D 3D TSV
US10196382 6 6 bis-Pyridazine compounds and their use in treating cancer AstraZeneca AB; Cancer Research Technology Limited 06/14/192D 3D TSV
US9724347 120 32 HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors Respivert, Ltd. 06/12/192D 3D TSV
US9725459 175 89 HGNC:2536 HGNC:2545 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I GRUNENTHAL GMBH 06/12/192D 3D TSV
US9725446 32 15 HGNC:8816 HGNC:11584 HGNC:14552 HGNC:11772 7-azaindole derivatives Merck Patent GmbH 06/12/192D 3D TSV
US9725465 406 201 HGNC:6342 HGNC:3765 Biaryl acetamide compounds and methods of use thereof Ambit Biosciences Corporation 06/12/192D 3D TSV
US10189849 50 45 HGNC:1771 HGNC:1773 CDK inhibitors G1 Therapeutics, Inc. 06/12/192D 3D TSV
US10195181 48 38 HGNC:16807 Carboxamide derivatives Novartis AG 06/12/192D 3D TSV
US9725433 164 146 HGNC:3763 HGNC:6307 Compounds as tyrosine kinase modulators ALLERGAN, INC. 06/12/192D 3D TSV
US10189853 42 15 HGNC:8803 HGNC:6307 HGNC:3236 Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents Duquesne University of the Holy Spirit 06/12/192D 3D TSV
US9725445 668 296 HGNC:6190 HGNC:6192 Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors Merck Sharp & Dohme Corp. 06/12/192D 3D TSV
US9725426 44 44 HGNC:2501 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. 06/12/192D 3D TSV
US9725436 51 17 Cytochrome P450 inhibitors and their method of use CORTENDO AB (PUBL) 06/12/192D 3D TSV
US10189859 236 91 HGNC:10597 Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine Nektar Therapeutics 06/12/192D 3D TSV
US10195178 99 98 HGNC:4498 GPR40 agonists in anti-diabetic drug combinations Janssen Pharmaceutica NV 06/12/192D 3D TSV
US10195201 75 32 HGNC:8777 Heteroaryl-pyrimidinone compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 06/12/192D 3D TSV
US9725442 422 338 HGNC:4502 Heterocyclic derivative having PGD2 receptor antagonist activity SHIONOGI & CO., LTD. 06/12/192D 3D TSV
US9724435 232 99 HGNC:3023 HGNC:11050 HGNC:8156 HGNC:11049 Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders THE UNIVERSITY OF MISSISSIPPI; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 06/12/192D 3D TSV
US9725441 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 06/12/192D 3D TSV
US9725434 62 31 HGNC:4849 HGNC:4848 Hydroxy-substituted orexin receptor antagonists MERCK SHARP & DOHME CORP. 06/12/192D 3D TSV
US10188639 3 3 HGNC:9236 Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone DeuteRx, LLC 06/12/192D 3D TSV
US10195186 101 49 HGNC:11186 N-substituted-5-substituted phthalamic acids as sortilin inhibitors H. Lundbeck A/S 06/12/192D 3D TSV
US10189791 5 5 HGNC:7873 Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole Trustees of Dartmouth College 06/12/192D 3D TSV
US9724352 7 7 HGNC:8979 Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Shanghai Haihe Pharmaceutical Co., Ltd. 06/12/192D 3D TSV
US9725439 29 20 HGNC:3236 Quinazoline derivative and preparation method therefor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 06/12/192D 3D TSV
US9725443 31 31 HGNC:10260 RORγ modulators Bristol-Myers Squibb Company 06/12/192D 3D TSV
US9725435 16 16 HGNC:3529 Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company 06/12/192D 3D TSV
US10196346 26 26 HGNC:4910 Substituted acethydrazide derivative, preparation method and use thereof Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China 06/12/192D 3D TSV
US10189854 347 343 HGNC:8781 Substituted pyrimidine compounds GRUENENTHAL GMBH 06/12/192D 3D TSV
US9725449 371 292 Tricyclic compounds as anticancer agents Bristol-Myers Squibb Company 06/12/192D 3D TSV
US9725430 18 12 HGNC:3521 HGNC:9642 Use of small molecule inhibitors targeting EYA tyrosine phosphatase CHILDREN HOSPITAL MEDICAL CENTER 06/12/192D 3D TSV
US10189796 9 9 HGNC:6018 [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. 06/12/192D 3D TSV
US9663479 6 6 HGNC:1403 γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders Novassay S.A. 06/04/192D 3D TSV
US9663475 31 28 HGNC:2529 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors Merck Patent GmbH 06/04/192D 3D TSV
US9663502 580 573 HGNC:10260 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663522 43 40 HGNC:10260 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663503 18 18 HGNC:1925 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof Cancer Research Technology Limited 06/04/192D 3D TSV
US9663530 136 67 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives Hoffmann-La Roche Inc. 06/04/192D 3D TSV
US9663496 493 492 HGNC:9377 AMPK-activating heterocyclic compounds and methods for using the same Rigel Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663526 468 113 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aminopyrimidinyl compounds Pfizer Inc. 06/04/192D 3D TSV
US9663498 53 53 HGNC:5301 Aromatic heterocyclic compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. 06/04/192D 3D TSV
US9663470 177 176 HGNC:5208 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International Gmbh 06/04/192D 3D TSV
US9663523 56 56 HGNC:13575 BET protein-inhibiting 5-aryltriazoleazepines BAYER PHARMA AKTIENGESELLSCHAFT 06/04/192D 3D TSV
US9663508 431 308 HGNC:10593 HGNC:10597 Biaryl acyl-sulfonamide compounds as sodium channel inhibitors Amgen Inc. 06/04/192D 3D TSV
US9663519 33 33 HGNC:882 Compounds useful as inhibitors of ATR kinase Vertex Pharmaceuticals Incorporated 06/04/192D 3D TSV
US9663515 16 16 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663527 4 4 HGNC:3529 Factor XIa inhibitors MERCK SHARP & DOHME CORP. 06/04/192D 3D TSV
US9663476 18 17 HGNC:11056 Glycine transporter-1 inhibitors AMGEN INC. 06/04/192D 3D TSV
US9663494 9 9 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffmann-La Roche Inc. 06/04/192D 3D TSV
US9663543 33 33 HGNC:2771 Phosphonate compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663525 125 119 HGNC:12477 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme Millennium Pharmaceuticals, Inc. 06/04/192D 3D TSV
US9663513 257 224 HGNC:8772 Pyrimidine PDE10 inhibitors Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663506 315 292 HGNC:4594 Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use Merck Sharp & Dohme Corp. 06/04/192D 3D TSV
US9663511 44 21 HGNC:3169 HGNC:14299 Sphingosine 1-phosphate receptor antagonists Arroyo BioSciences, LLC 06/04/192D 3D TSV
US9663528 23 22 HGNC:10966 Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections Gilead Sciences, Inc. 06/04/192D 3D TSV
US9663510 28 28 HGNC:12401 Substituted triazolopyridines and their use as TTK inhibitors BAYER PHARMA AKTIENGESELLSCHAFT; BAYER INTELLECTUAL PROPERTY GMBH 06/04/192D 3D TSV
US9663529 96 96 HGNC:10252 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Bristol-Myers Squibb Company 06/04/192D 3D TSV
US9663463 21 21 HGNC:8156 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose SANWA KAGAKU KENKYUSHO CO., LTD.; UBE INDUSTRIES, LTD. 06/03/192D 3D TSV
US9663465 50 26 HGNC:5299 HGNC:108 Acetylcholinesterase inhibitors and promnesiant serotonin 5-HT4 receptor agonists, their methods of preparation and the pharmaceutical compositions containing the same UNIVERSITE DE CAEN 06/03/192D 3D TSV
US9662330 243 240 HGNC:10436 Aminopyrimidine derivatives for use as modulators of kinase activity Merck Patent GmbH 06/03/192D 3D TSV
US9662339 296 295 HGNC:6710 Benzodioxane inhibitors of leukotriene production for combination therapy Boehringer Ingelheim International GmbH 06/03/192D 3D TSV
US9662310 68 66 HGNC:2300 Cyclopropanecarboxylic acid derivative DAIICHI SANKYO COMPANY, LIMITED 06/03/192D 3D TSV
US9662327 402 393 Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer AGIOS PHARMACEUTICALS, INC 06/03/192D 3D TSV
US9663469 319 307 RORγ modulators Bristol-Myers Squibb Company 06/03/192D 3D TSV
US9663460 209 209 HGNC:1603 Sulfur derivatives as chemokine receptor modulators ALLERGAN, INC. 06/03/192D 3D TSV
US10189845 867 207 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors Array BioPharma Inc. 05/29/192D 3D TSV
US9636336 248 55 HGNC:1952 Aminoester derivatives CHIESI FARMACEUTICI S.p.A. 05/29/192D 3D TSV
US9637499 10 10 HGNC:8780 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors LEO PHARMA A/S 05/29/192D 3D TSV
US9637486 28 28 HGNC:1133 Btk inhibitors MERCK SHARP & DOHME CORP. 05/29/192D 3D TSV
US9637484 20 20 HGNC:17989 Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.; JIANGSU HENGRUI MEDICINE CO., LTD. 05/29/192D 3D TSV
US9636335 44 43 HGNC:5299 Heteroaryl compounds as 5-HT4 receptor ligands SUVEN LIFE SCIENCES LIMITED 05/29/192D 3D TSV
US9637488 37 33 HGNC:8978 Heterocyclic compounds as inhibitors of class I PI3KS TBA 05/29/192D 3D TSV
US9637455 21 21 Heterocyclic sulfone RORγ modulators Bristol-Myers Squibb Company 05/29/192D 3D TSV
US9636339 64 32 HGNC:2592 HGNC:2591 Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors Hoffman-La Roche Inc. 05/29/192D 3D TSV
US9636338 48 23 HGNC:2592 HGNC:2591 Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase Hoffmann-La Roche Inc. 05/29/192D 3D TSV
US9637487 34 34 HGNC:1133 Purinone compounds as kinase inhibitors PHARMACYCLICS LLC 05/29/192D 3D TSV
US10189841 544 538 HGNC:12607 Purinones as ubiquitin-specific protease 1 inhibitors FORMA Therapeutics, Inc. 05/29/192D 3D TSV
US9636337 315 292 HGNC:4594 Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use Merck Sharp & Dohme Corp. 05/29/192D 3D TSV
US9637472 391 389 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 05/29/192D 3D TSV
US9637496 1033 378 HGNC:4849 HGNC:4848 Substituted 7-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 05/29/192D 3D TSV
US9637493 47 45 Substituted pyrrolopyrimidines as HDM2 inhibitors Merck Sharp & Dohme Corp. 05/29/192D 3D TSV
US10189840 40 40 HGNC:11892 Substituted tricyclic heterocyclic compounds Bristol-Myers Squibb Company 05/29/192D 3D TSV
US9636330 15 15 HGNC:3357 Tetrahydrocarboline derivative ONO PHARMACEUTICAL CO., LTD. 05/29/192D 3D TSV
US10189838 117 114 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection Hoffman-La Roche Inc. 05/26/192D 3D TSV
US10189835 22 21 Derivatives and methods of treating hepatitis B infections NOVIRA THERAPEUTICS, INC. 05/26/192D 3D TSV
US10189831 182 181 Non-nucleoside reverse transcriptase inhibitors Merck Sharp & Dohme Corp. 05/26/192D 3D TSV
US10189836 398 189 HGNC:6190 HGNC:6192 Therapeutic compounds, compositions and methods of use thereof Genentech, Inc. 05/26/192D 3D TSV
US10188615 195 171 HGNC:10294 HGNC:9864 HGNC:9866 HGNC:9865 HGNC:10477 Alkoxy compounds for disease treatment ACUCELA INC. 05/25/192D 3D TSV
US10188653 55 55 HGNC:16940 Diacylglycerol acyltransferase 2 inhibitors Pfizer Inc. 05/25/192D 3D TSV
US10189819 87 86 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme, Corp.; Mochida Paraceuticals Co., Ltd. 05/25/192D 3D TSV
US10189794 194 192 HGNC:3691 Heteroaryl compounds and uses thereof Celgene CAR LLC; Sanofi 05/25/192D 3D TSV
US10188756 189 27 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 Imaging histone deacetylases with a radiotracer using positron emission tomography The General Hospital Corporation 05/25/192D 3D TSV
US10189829 145 139 HGNC:1133 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. 05/25/192D 3D TSV
US10189805 8 8 HGNC:10943 Metabolism probes for therapy and diagnosis Vanderbilt University 05/25/192D 3D TSV
US10188758 8 5 HGNC:11050 HGNC:11048 Organic compounds INTRA-CELLULAR THERAPIES, INC. 05/25/192D 3D TSV
US10188627 67 32 HGNC:9235 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof Mitobridge, Inc.; Salk Institute for Biological Studies 05/25/192D 3D TSV
US10188667 22 11 HGNC:4591 Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives ALLERGAN, INC. 05/25/192D 3D TSV
US10188642 104 103 HGNC:12401 Pharmacologically active compounds Cancer Research Technology Limited 05/25/192D 3D TSV
US10189809 198 191 HGNC:4685 SGC stimulators Ironwood Pharmaceuticals, Inc. 05/25/192D 3D TSV
US10189788 90 73 HGNC:9600 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents BAYER PHARMA AKTIENGESELLSCHAFT 05/25/192D 3D TSV
US10189816 194 162 Substituted pyridines as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO. 5) LIMITED 05/25/192D 3D TSV
US10189807 7 7 HGNC:23 Tetrahydrothiophene-based GABA aminotransferase inactivators Northwestern University 05/25/192D 3D TSV
US9630945 80 80 HGNC:10555 Autotaxin inhibitors Novartis AG 05/20/192D 3D TSV
US9630929 138 57 HGNC:10593 HGNC:10597 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 05/20/192D 3D TSV
US9629836 101 100 Compounds and compositions as inhibitors of MEK NOVARTIS AG 05/20/192D 3D TSV
US9630956 151 149 HGNC:882 Compounds useful as inhibitors of ATR kinase Vertex Pharmaceuticals Incorporated 05/20/192D 3D TSV
US9630965 73 63 HGNC:5253 HGNC:1735 Fused amino pyridine as HSP90 inhibitors Curis, Inc. 05/20/192D 3D TSV
US9630914 86 19 HGNC:3553 HGNC:9605 Multitarget FAAH and COX inhibitors and therapeutical uses thereof Fondazione Istituto Italiano Di Tecnologia; The Regents of the University of California; Alma Mater Studiorum—Universita' Di Bologna 05/20/192D 3D TSV
US9630949 143 77 HGNC:6932 HGNC:6929 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT 05/20/192D 3D TSV
US9630931 29 29 HGNC:1925 Pharmaceutically active pyrazine derivatives SENTINEL ONCOLOGY LIMITED 05/20/192D 3D TSV
US10183937 838 407 HGNC:15459 HGNC:8534 1,3-thiazol-2-yl substituted benzamides Bayer Aktiengesellschaft 05/16/192D 3D TSV
US10179123 89 74 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 05/16/192D 3D TSV
US10174024 77 60 HGNC:13575 5H-pyrido[3,2-B]indole compounds as anticancer agents Bristol-Myers Squibb Company 05/16/192D 3D TSV
US10174035 234 135 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors Daiichi Sankyo Company, Limited 05/16/192D 3D TSV
US10183940 124 78 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists Boehringer Ingelheim International GmbH 05/16/192D 3D TSV
US10183025 206 200 HGNC:3357 Autotaxin inhibitors Novartis AG 05/16/192D 3D TSV
US10174049 36 36 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors Glaxosmithkline LLC 05/16/192D 3D TSV
US10179761 52 28 HGNC:8157 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases UNIVERSITE DE LILLE 2 DROIT ET SANTE; CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) 05/16/192D 3D TSV
US10174030 116 116 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 05/16/192D 3D TSV
US10174037 579 205 HGNC:8777 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 05/16/192D 3D TSV
US10183939 56 21 Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers Redx Pharma PLC 05/16/192D 3D TSV
US10174044 63 62 HGNC:19679 Fused pyridines as kinase inhibitors Bristol-Myers Squibb Company 05/16/192D 3D TSV
US10183938 448 300 HGNC:5297 HGNC:1960 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors Axovant Sciences GmbH 05/16/192D 3D TSV
US10174023 22 22 HGNC:270 Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD 05/16/192D 3D TSV
US10174026 297 93 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 05/16/192D 3D TSV
US10179769 211 103 HGNC:9886 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/16/192D 3D TSV
US10183928 8 4 HGNC:9967 Inhibitors of RET BLUEPRINT MEDICINES CORPORATION 05/16/192D 3D TSV
US10179773 10 10 HGNC:15513 Isoxazole carboxamides as irreversible SMYD inhibitors EPIZYME, INC. 05/16/192D 3D TSV
US10183942 112 16 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK kinase inhibitor compounds for treatment of respiratory disease THERAVANCE BIOPHARMA R&D IP, LLC 05/16/192D 3D TSV
US10179804 132 132 HGNC:6932 Melanocortin receptor-specific peptides Palatin Technologies, Inc. 05/16/192D 3D TSV
US10183954 14 14 HGNC:15631 Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection Hoffmann-La Roche Inc. 05/16/192D 3D TSV
US10183913 128 64 HGNC:11050 HGNC:5295 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. 05/16/192D 3D TSV
US10183947 51 49 HGNC:435 Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB 05/16/192D 3D TSV
US10174020 10 10 HGNC:3529 Pyridone or pyrimidone derivative, preparation method therefor and application thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. 05/16/192D 3D TSV
US10183944 614 335 HGNC:6192 HGNC:11491 Pyrimido-pyridazinone compounds and methods of use thereof Asana BioSciences, LLC 05/16/192D 3D TSV
US10174040 143 110 HGNC:1373 Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 05/16/192D 3D TSV
US10183931 91 36 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 05/16/192D 3D TSV
US10179791 122 42 HGNC:3167 HGNC:3165 HGNC:14299 Spiro-cyclic amine derivatives as S1P modulators AbbVie B.V.; AbbVie, Inc. 05/16/192D 3D TSV
US10183953 990 258 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 05/16/192D 3D TSV
US10183932 357 143 HGNC:3529 Substituted oxopyridine derivatives and use thereof cardiovascular disorders Bayer Pharma Aktiengesellschaft 05/16/192D 3D TSV
US10174028 1162 716 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 05/16/192D 3D TSV
US10174027 1162 716 HGNC:9967 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 05/16/192D 3D TSV
US10183009 122 121 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 05/16/192D 3D TSV
US10183946 92 45 HGNC:2160 HGNC:2159 Triazolo[4,5-D]pyrimidines HOFFMANN-LA ROCHE INC. 05/16/192D 3D TSV
US10183917 18 17 HGNC:7967 Tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. 05/16/192D 3D TSV
US10183021 388 384 HGNC:4685 sGC stimulators Ironwood Pharmaceuticals, Inc. 05/16/192D 3D TSV
US10174016 873 411 HGNC:2596 HGNC:2637 HGNC:15459 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 1,3-thiazol-2-yl substituted benzamides BEYER AKTIENGESELLSCHAFT 05/15/192D 3D TSV
US9624197 30 15 HGNC:4849 HGNC:4848 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. 05/15/192D 3D TSV
US9624210 3 3 HGNC:11491 Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors MERCK SHARP & DOHME CORP. 05/15/192D 3D TSV
US10173985 34 18 HGNC:10593 HGNC:10597 Aminoindazole derivatives as sodium channel inhibitors Almirall, S.A. 05/15/192D 3D TSV
US9624159 8 8 HGNC:9596 Aniline derivatives, their preparation and their therapeutic application SANOFI 05/15/192D 3D TSV
US10174013 42 27 HGNC:6251 HGNC:3765 Benzimidazole derivatives as kinase inhibitors SELVITA S.A. 05/15/192D 3D TSV
US10174000 62 32 HGNC:17967 Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. 05/15/192D 3D TSV
US9624235 20 15 HGNC:587 Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity University of Pittsburgh—Of the Commonwealth System of Higher Education 05/15/192D 3D TSV
US9624213 207 207 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 05/15/192D 3D TSV
US9624217 159 156 HGNC:10260 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, Inc. 05/15/192D 3D TSV
US9624175 82 61 Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. 05/15/192D 3D TSV
US9624194 25 22 HGNC:10597 Heteroaryl compounds as sodium channel blockers Purdue Pharma L.P. 05/15/192D 3D TSV
US9624234 25 24 HGNC:338 Heterocyclic compounds and methods for their use NOVARTIS AG 05/15/192D 3D TSV
US9624243 85 83 HGNC:338 Heterocyclic compounds and methods of their use NOVARTIS AG 05/15/192D 3D TSV
US10174011 307 98 HGNC:3023 HGNC:5286 Heterocyclic compounds, process for preparation of the same and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; SUZHOU VIGONVITA LIFE SCIENCES CO., LTD.; TOPHARMAN SHANDONG CO., LTD. 05/15/192D 3D TSV
US10173996 511 154 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/15/192D 3D TSV
US10174003 329 106 HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 05/15/192D 3D TSV
US9624188 12 12 HGNC:6059 IDO inhibitors Bristol-Myers Squibb Company 05/15/192D 3D TSV
US9624228 377 370 HGNC:6871 Inhibitors of ERK and methods of use Kura Oncology, Inc. 05/15/192D 3D TSV
US9624201 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC.; CHUGAI PHARMACEUTICAL CO. 05/15/192D 3D TSV
US9623028 67 28 HGNC:2068 HGNC:2069 HGNC:1470 HGNC:12401 Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof Signal Pharmaceuticals, LLC 05/15/192D 3D TSV
US10173988 15 5 HGNC:7889 HGNC:7891 HGNC:2578 N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine GLUCOX BIOTECH AB 05/15/192D 3D TSV
US9623021 24 12 HGNC:3467 HGNC:3468 Nuclear receptor binding agents GTX, Inc. 05/15/192D 3D TSV
US9624247 107 27 HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease NOVARTIS AG 05/15/192D 3D TSV
US9624246 30 15 HGNC:17967 Pyridazinone macrocycles as IRAK inhibitors and uses thereof Merck Patent GmbH 05/15/192D 3D TSV
US10173995 7 6 HGNC:8979 Pyridine compounds used as PI3 kinase inhibitors Teligene Ltd. 05/15/192D 3D TSV
US9624218 112 32 HGNC:270 HGNC:11941 HGNC:15677 Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors Eli Lilly and Company 05/15/192D 3D TSV
US10174007 40 18 HGNC:6315 Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors Pfizer Inc. 05/15/192D 3D TSV
US9624205 12 6 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. 05/15/192D 3D TSV
US9624199 21 21 HGNC:277 Substituted bipiperidinyl derivatives Bayer Pharma Aktiengesellschaft 05/15/192D 3D TSV
US10174015 92 46 HGNC:3553 HGNC:736 Substituted heterocyclic derivative, preparation method and use thereof Xiamen University 05/15/192D 3D TSV
US9624198 15 14 HGNC:277 Substituted piperidinyltetrahydroquinolines Bayer Pharma Aktiengesellschaft 05/15/192D 3D TSV
US10172868 103 52 HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. 05/15/192D 3D TSV
US10173991 590 589 HGNC:6623 Sulfone amide linked benzothiazole inhibitors of endothelial lipase Bristol-Myers Squibb Company 05/15/192D 3D TSV
US9624241 574 277 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation; Incyte Holdings Corporation 05/15/192D 3D TSV
US10173990 17 17 HGNC:17989 URAT1 inhibitor Nippon Chemiphar Co., Ltd.; J-Pharma Co., Ltd.; DeThree Res. Lab. Inc. 05/15/192D 3D TSV
US9617246 74 36 HGNC:4849 HGNC:4848 Thioether-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. 05/10/192D 3D TSV
US9617225 165 150 HGNC:1780 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity VIROSTATICS SRL 05/08/192D 3D TSV
US9617262 62 62 Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland UC 05/08/192D 3D TSV
US9617267 761 86 HGNC:2596 HGNC:9829 HGNC:1097 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 05/08/192D 3D TSV
US9617226 45 44 HGNC:895 Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases AbbVie Deutschland GmbH & Co. KG 05/08/192D 3D TSV
US9617273 122 68 HGNC:270 HGNC:272 HGNC:15677 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. 05/08/192D 3D TSV
US9617259 45 45 HGNC:14063 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 05/08/192D 3D TSV
US9617242 237 77 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 05/08/192D 3D TSV
US9617281 8 8 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. 05/08/192D 3D TSV
US9617260 34 34 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffmann-La Roche Inc. 05/08/192D 3D TSV
US9617282 218 216 HGNC:17967 Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases BIOGEN MA INC. 05/08/192D 3D TSV
US9617269 97 96 HGNC:8795 N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof Sun Yat-Sen University; University of North Carolina at Chapel Hill 05/08/192D 3D TSV
US9617239 89 88 HGNC:4696 Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase North Carolina Central University; The University of North Carolina at Chapel Hill 05/08/192D 3D TSV
US9617250 26 13 HGNC:3167 HGNC:3165 Pyridin-4-yl derivatives ACTELION PHARMACEUTICALS LTD. 05/08/192D 3D TSV
US9617258 611 315 HGNC:6193 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides Pfizer Inc. 05/08/192D 3D TSV
US9617261 11 11 HGNC:6840 Substituted pyridinone compounds as MEK inhibitors CMG PHARMACEUTICAL CO., LTD. 05/08/192D 3D TSV
US9617271 72 72 HGNC:8772 Triazolo compounds Hoffmann-La Roche Inc. 05/08/192D 3D TSV
US9617272 20 10 HGNC:11708 HGNC:6059 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization NewLink Genetics Corporation 05/08/192D 3D TSV
US9616063 30 15 HGNC:7218 HGNC:12015 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase AstraZeneca AB 05/07/192D 3D TSV
US9617222 48 48 HGNC:6307 Alkynyl indazole derivative and use thereof SENJU PHARMACEUTICAL CO., LTD. 05/07/192D 3D TSV
US9616064 137 77 HGNC:10251 HGNC:10252 Rho kinase inhibitors and methods of use H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 05/07/192D 3D TSV
US9616059 12 4 HGNC:5465 HGNC:11393 HGNC:427 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. 05/07/192D 3D TSV
US10172856 122 122 HGNC:17383 2,4-diaminopyrimidine derivatives as histamine H4 modulators Janssen Pharmaceutica NV 04/30/192D 3D TSV
US10172859 919 330 HGNC:6251 HGNC:9413 Arylquinazolines Merck Patent GmbH 04/30/192D 3D TSV
US9611269 84 42 HGNC:6190 HGNC:6192 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors Incyte Corporation; Incyte Holdings Corporation 04/30/192D 3D TSV
US10172858 368 95 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:3942 HGNC:8977 Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC 04/30/192D 3D TSV
US9611270 21 14 HGNC:2593 HGNC:2600 Inhibitors of CYP17A1 UNIVERSITY OF KANSAS 04/30/192D 3D TSV
US10172837 11 11 HGNC:1368 Insulin sensitisers and methods of treatment Naia Metabolic, Inc. 04/30/192D 3D TSV
US9611275 61 59 HGNC:7056 Permeable glycosidase inhibitors and uses thereof ALECTOS THERAPEUTICS, INC.; MERCK SHARP & DOHME CORP. 04/30/192D 3D TSV
US10172843 81 79 HGNC:2545 Piperidine derivatives Hoffmann-La Roche Inc. 04/30/192D 3D TSV
US9611277 990 259 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/30/192D 3D TSV
US10172845 2116 814 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 04/30/192D 3D TSV
US10172851 1229 556 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 04/30/192D 3D TSV
US10172814 213 157 HGNC:9605 Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof BAYER PHARMA AKTIENGESELLSCHAFT 04/30/192D 3D TSV
US10172864 1070 389 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 04/30/192D 3D TSV
US9611229 39 39 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders LABORATORIOS DEL DR. ESTEVE S.A. 04/29/192D 3D TSV
US9611249 35 34 HGNC:4617 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. 04/29/192D 3D TSV
US9611224 350 177 HGNC:590 HGNC:591 Antiproliferative benzo [B] azepin-2-ones HOFFMANN-LA ROCHE INC. 04/29/192D 3D TSV
US9610264 16 15 HGNC:6162 Compounds for the treatment and prevention of retroviral infections KFLP BIOTECH, LLC 04/29/192D 3D TSV
US9610299 42 12 HGNC:6833 HGNC:6834 HGNC:404 Compounds for the treatment of addiction Gilead Sciences, Inc. 04/29/192D 3D TSV
US9611221 199 93 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 04/29/192D 3D TSV
US9610322 10 10 HGNC:5381 Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof President and Fellows of Harvard College 04/29/192D 3D TSV
US9611232 8 8 HGNC:6293 Oxazolidinone and imidazolidinone compounds Hoffmann-La Roche Inc. 04/29/192D 3D TSV
US9611261 846 397 HGNC:2529 HGNC:933 Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use Amgen Inc. 04/29/192D 3D TSV
US9611222 152 151 HGNC:10597 Pyridine compounds and the uses thereof Purdue Pharma L.P. 04/29/192D 3D TSV
US9611262 489 129 HGNC:4849 HGNC:4848 Substituted 2-azabicycles and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611251 546 192 HGNC:4849 HGNC:4848 Substituted piperidine compounds and their use as orexin receptor modulators Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611259 3 3 HGNC:2433 Substituted pyridine derivatives useful as C-FMS kinase inhibitors Janssen Pharmaceutica NV 04/29/192D 3D TSV
US9611267 699 232 HGNC:3690 HGNC:3689 HGNC:3688 Substituted tricyclic compounds as FGFR inhibitors Incyte Holdings Corporation; Incyte Corporation 04/29/192D 3D TSV
US9611252 146 145 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 04/29/192D 3D TSV
US9611265 241 79 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:2433 Tropomyosin-related kinase (TRK) inhibitors GENZYME CORPORATION 04/29/192D 3D TSV
US10167299 125 111 HGNC:1606 HGNC:6251 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 04/24/192D 3D TSV
US10167282 14 5 HGNC:6251 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer CANCER RESEARCH TECHNOLOGY LIMITED; INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) 04/24/192D 3D TSV
US9605007 135 118 HGNC:6251 HGNC:933 HGNC:2625 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides Pfizer Inc. 04/24/192D 3D TSV
US10167261 20 9 2-oxo-3,4-dihydroquinolin-6-yl sulphonamide CPDS and their use as plant growth regulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; SYNGENTA PARTICIPATIONS AG 04/24/192D 3D TSV
US9605006 15 15 HGNC:933 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines Hoffmann-La Roche Inc. 04/24/192D 3D TSV
US9605005 199 198 HGNC:5960 Alkynyl alcohols and methods of use Genentech, Inc. 04/24/192D 3D TSV
US10167292 172 37 Benzodiazepines as bromodomain inhibitors Catalyst Therapeutics Pty Ltd. 04/24/192D 3D TSV
US9605008 21 21 HGNC:8784 Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US10167279 409 305 HGNC:9829 Compounds and compositions as RAF kinase inhibitors Novartis AG 04/24/192D 3D TSV
US10167276 207 69 Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. 04/24/192D 3D TSV
US9604998 109 95 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 04/24/192D 3D TSV
US9605022 39 20 HGNC:592 Macrocyclic compounds for inhibition of inhibitors of apoptosis Ensemble Therapeutics Corporation 04/24/192D 3D TSV
US9605024 9 9 HGNC:3540 PAR4 agonist peptides Bristol-Myers Squibb Company 04/24/192D 3D TSV
US10167256 8 4 HGNC:3023 Psychotrophic agents and uses thereof LB PHARMACEUTICALS INC. 04/24/192D 3D TSV
US10167313 102 25 HGNC:1506 HGNC:1508 HGNC:1504 HGNC:1499 HGNC:1511 Selective caspase inhibitors and uses thereof Genesis Technologies Limited 04/24/192D 3D TSV
US10167285 48 16 HGNC:3430 HGNC:5253 Small-molecule HSP90 inhibitors Memorial Sloan Kettering Cancer Center 04/24/192D 3D TSV
US10166249 952 228 HGNC:3167 HGNC:10817 Substituted bicyclic compounds Bristol-Myers Squibb Company 04/24/192D 3D TSV
US10167280 108 47 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US10167264 10 5 HGNC:3236 Substituted pyrimidines useful as EGFR-T790M kinase inhibitors Jiangsu Medolution Ltd 04/24/192D 3D TSV
US10167270 175 127 HGNC:4177 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity Northwestern University 04/24/192D 3D TSV
US10167281 213 119 HGNC:8537 Substituted thiazole or oxazole P2X7 receptor antagonists Axxam S.P.A. 04/24/192D 3D TSV
US10166216 151 151 Substituted triazoles useful as Axl inhibitors Rigel Pharmaceuticals, Inc. 04/24/192D 3D TSV
US10167273 111 107 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases Takeda Pharmaceutical Company Limited 04/24/192D 3D TSV
US10167296 99 67 HGNC:7110 HGNC:7111 Sulfoximine substituted quinazolines for pharmaceutical compositions EVOTEC INTERNATIONAL GMBH 04/24/192D 3D TSV
US10166239 241 78 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:2433 Tropomyosin-related kinase (Trk) inhibitors Genzyme Corporation 04/24/192D 3D TSV
US10167293 76 76 HGNC:386 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones BAYER PHARMA AKTIENGESELLSCHAFT 04/24/192D 3D TSV
US9603834 27 26 HGNC:1603 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. 04/23/192D 3D TSV
US9604984 934 465 HGNC:6190 HGNC:6192 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof Genentech, Inc. 04/23/192D 3D TSV
US9604960 81 27 HGNC:11050 HGNC:11048 HGNC:11049 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof Albany Molecular Research, Inc. 04/23/192D 3D TSV
US9604944 6 2 HGNC:5286 Arylpiperazine derivatives and methods of utilizing same REVIVA PHARMACEUTICALS, INC. 04/23/192D 3D TSV
US9603833 88 42 HGNC:6833 HGNC:6834 HGNC:550 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. 04/23/192D 3D TSV
US9604977 516 251 HGNC:3560 HGNC:3559 Bicyclic thiophenylamide compounds Hoffman-La Roche Inc. 04/23/192D 3D TSV
US9604926 226 99 HGNC:3023 HGNC:4584 HGNC:11050 HGNC:8156 HGNC:11048 HGNC:11049 Highly selective sigma receptor radioligands THE UNIVERSITY OF MISSISSIPPI 04/23/192D 3D TSV
US9604961 509 153 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 04/23/192D 3D TSV
US9603889 86 43 HGNC:592 IAP antagonists Bristol-Myers Squibb Company 04/23/192D 3D TSV
US9604989 159 80 HGNC:391 HGNC:392 Imidazopyridazines as Akt kinase inhibitors BAYER INTELLECTUAL PROPERTY GMBH; BAYER PHARMA AKTIENGESELLSCHAFT 04/23/192D 3D TSV
US9603854 119 113 HGNC:990 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 04/23/192D 3D TSV
US9604931 24 12 HGNC:3473 HGNC:3471 Nuclear receptor binding agents GTx, Inc.; THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 04/23/192D 3D TSV
US9604982 678 116 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/23/192D 3D TSV
US9603836 28 27 HGNC:6059 Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors ITEOS THERAPEUTICS 04/23/192D 3D TSV
US9603819 13 13 HGNC:7154 Substituted aminobutyric derivatives as neprilysin inhibitors NOVARTIS AG 04/23/192D 3D TSV
US9604945 7 7 HGNC:11049 Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders Caliper Life Sciences, Inc. 04/23/192D 3D TSV
US10166226 9 9 CGRP receptor antagonists Heptares Therapeutics Limited 04/11/192D 3D TSV
US10166229 10 10 HGNC:1504 Compounds and methods for the treatment of cancer The Board of Trustees of the University of Illinois 04/11/192D 3D TSV
US10155763 7 7 HGNC:11772 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors TIUMBIO CO., LTD. 04/10/192D 3D TSV
US10155750 76 38 HGNC:4849 HGNC:4848 Amidoethyl azole orexin receptor antagonists Merck Sharp & Dohme Corp. 04/10/192D 3D TSV
US10155760 237 234 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 04/10/192D 3D TSV
US10155765 66 66 HGNC:17967 Carboxamide inhibitors of IRAK4 activity Merck Sharp & Dohme Corp. 04/10/192D 3D TSV
US10155769 91 91 HGNC:1406 Fused azaheterocyclic compounds and their use as AMPA receptor modulators Janssen Pharmaceutica NV 04/10/192D 3D TSV
US10155768 520 197 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 04/10/192D 3D TSV
US10155752 16 12 HGNC:10597 Indazoles and use thereof Purdue Pharma L.P. 04/10/192D 3D TSV
US10155733 27 27 HGNC:1952 N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same Conopco, Inc. 04/10/192D 3D TSV
US10155731 131 127 HGNC:9958 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION; SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. 04/10/192D 3D TSV
US10155751 81 27 Pyrazolyl-substituted heteroaryls and their use as medicaments Boehringer Ingelheim International GmbH 04/10/192D 3D TSV
US10155732 5 5 HGNC:10452 Ribonucleotide reductase inhibitors and methods of use City of Hope 04/10/192D 3D TSV
US10155972 10 6 HGNC:11708 Screening method Iomet Pharma Ltd. 04/10/192D 3D TSV
US10166214 284 169 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 04/10/192D 3D TSV
US10155775 8 8 HGNC:3009 Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors Centaurus Biopharma Co., Ltd.; Chia Tai Tianqing Pharmaceutical Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd. 04/10/192D 3D TSV
US10155764 114 111 Therapeutic compounds and uses thereof GENENTECH, INC; CONSTELLATION PHARMACEUTICALS, INC. 04/10/192D 3D TSV
US10150759 3 3 HGNC:3527 1,4-pyridone bicycic heteroaryl compounds Epizyme, Inc. 04/09/192D 3D TSV
US10150755 127 89 HGNC:6857 HGNC:7590 HGNC:11892 ASK1 inhibitor compounds and uses thereof SEAL ROCK THERAPEUTICS, INC. 04/09/192D 3D TSV
US9657003 40 20 Androgen receptor modulating compounds ORION CORPORATION 04/09/192D 3D TSV
US10155722 20 20 HGNC:5383 Antitumor compound targeting IDH2 mutation and method of use thereof Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 04/09/192D 3D TSV
US10155002 334 185 HGNC:3527 Aryl- or heteroaryl-substituted benzene compounds Epizyme, Inc. 04/09/192D 3D TSV
US9657001 65 65 HGNC:6719 Compounds and uses ASTRAZENECA AB 04/09/192D 3D TSV
US10150760 390 224 HGNC:339 Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor AMGEN INC. 04/09/192D 3D TSV
US9656996 17 17 HGNC:11892 Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. 04/09/192D 3D TSV
US9657009 168 150 HGNC:17967 Heteroaryl substituted pyridyl compounds useful as kinase modulators Bristol-Myers Squibb Company 04/09/192D 3D TSV
US10150763 76 38 HGNC:4852 HGNC:14064 Histone deacetylase inhibitors and their use in therapy Karus Therapeutics Limited 04/09/192D 3D TSV
US9656988 1351 352 HGNC:1133 HGNC:6193 HGNC:3236 HGNC:6524 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC 04/09/192D 3D TSV
US9656991 121 70 HGNC:9753 Inhibitors of glutaminyl cyclase PROBIODRUG AG 04/09/192D 3D TSV
US10150765 843 286 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/09/192D 3D TSV
US10150766 102 62 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 04/09/192D 3D TSV
US10150758 30 29 HGNC:10894 PRMT5 inhibitors and uses thereof Epizyme, Inc. 04/09/192D 3D TSV
US10155727 217 103 HGNC:4586 HGNC:6251 Pyrazoles JANSSEN PHARMACEUTICALS, INC. 04/09/192D 3D TSV
US9657007 36 18 HGNC:8979 HGNC:8978 HGNC:8977 HGNC:8976 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD. 04/09/192D 3D TSV
US10150764 139 70 HGNC:3527 Substituted benzene compounds Epizyme, Inc. 04/09/192D 3D TSV
US9657015 73 49 HGNC:3309 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 04/09/192D 3D TSV
US10150787 10 10 HGNC:9650 TC-PTP inhibitors as APC activators for immunotherapy TBA 04/09/192D 3D TSV
US9657033 112 92 HGNC:10260 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 04/09/192D 3D TSV
US10150767 46 45 Therapeutic compounds and uses thereof Genentech, Inc.; Constellation Pharmaceuticals Inc. 04/09/192D 3D TSV
US10150762 178 86 HGNC:10260 Trifluoromethyl alcohols as modulators of RORγt Janssen Pharmaceutica, NV 04/09/192D 3D TSV
US9656975 20 10 HGNC:4579 Bicyclo[3.2.1]octyl amide derivatives and uses of same H. Lundbeck A/S 04/08/192D 3D TSV
US9655879 188 94 HGNC:9490 HGNC:9475 Heteroarylcarboxylic acid ester derivative EA Pharma Co., Ltd. 04/08/192D 3D TSV
US9656961 158 54 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 04/08/192D 3D TSV
US9656968 122 102 HGNC:10597 Pyrimidines as sodium channel blockers TBA 04/08/192D 3D TSV
US9656955 808 790 HGNC:7044 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Inc.; AbbVie Deutschland GmbH & Co. KG 04/08/192D 3D TSV
US9656962 87 47 HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 Ring-contracted morphinans and the use thereof Purdue Pharma L.P. 04/08/192D 3D TSV
US9656959 90 77 HGNC:10597 Substituted pyridines as sodium channel blockers Purdue Pharma L.P. 04/08/192D 3D TSV
US9649308 246 175 HGNC:8537 Benzamide-containing compounds and their use in the treatment of pain H. Lundbeck A/S 04/03/192D 3D TSV
US9650377 368 161 HGNC:4597 HGNC:4593 Diazepinone derivatives Novartis AG 04/03/192D 3D TSV
US9650366 16 13 HGNC:6307 HGNC:8804 HGNC:9437 Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 04/03/192D 3D TSV
US9650362 20 10 HGNC:9753 Inhibitors PROBIODRUG AG 04/03/192D 3D TSV
US9650336 11 11 Mono-fluoro beta-secretase inhibitors ASTRAZENECA AB 04/03/192D 3D TSV
US9650358 339 335 HGNC:1780 Pyridine CDK9 kinase inhibitors AbbVie Inc. 04/03/192D 3D TSV
US9650371 37 37 HGNC:933 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity Shionogi & Co., Ltd. 04/03/192D 3D TSV
US9649309 1394 400 HGNC:7027 HGNC:12446 HGNC:3765 Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity The University of North Carolina at Chapel Hill 04/03/192D 3D TSV
US10150740 15 15 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection Hoffmann-La Roche Inc. 03/31/192D 3D TSV
US10150728 704 701 HGNC:85 Alkylene derivatives SHIONOGI & CO., LTD. 03/31/192D 3D TSV
US10144746 350 344 HGNC:6371 Bridged bicyclic kallikrein inhibitors Global Blood Therapeutics, Inc. 03/31/192D 3D TSV
US10150743 28 13 HGNC:15631 HGNC:15632 Carboxylic acid compounds Sumitomo Dainippon Pharma Co., Ltd. 03/31/192D 3D TSV
US10149839 156 72 HGNC:3467 Chemical compounds AstraZeneca AB 03/31/192D 3D TSV
US10149841 6 6 HGNC:1232 Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. 03/31/192D 3D TSV
US10150747 65 31 Compounds for the treatment of hepatitis C Bristol-Myers Squibb Company 03/31/192D 3D TSV
US10149835 7 7 HGNC:7967 Isoxazole derivatives as FXR agonists and methods of use thereof Elmore Patent Law Group, P.C. 03/31/192D 3D TSV
US10149840 3 3 HGNC:9221 OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 03/31/192D 3D TSV
US10150751 82 41 HGNC:4849 HGNC:4848 Pyrrolidine orexin receptor antagonists Merck Sharp & Dohme Corp. 03/31/192D 3D TSV
US10143681 183 71 HGNC:6371 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp. 03/30/192D 3D TSV
US10138245 14 14 HGNC:8772 Fused triazole derivatives as phosphodiesterase 10A inhibitors CELON PHARMA S.A. 03/30/192D 3D TSV
US10143668 5 5 HGNC:4879 Hydroxy-substituted amino and ammonium derivatives and their medical use GRI BIO, INC. 03/30/192D 3D TSV
US10138253 38 28 Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO.5) LIMITED 03/30/192D 3D TSV
US10143746 28 28 Immunomodulators Bristol-Myers Squibb Company 03/30/192D 3D TSV
US10144729 8 8 HGNC:7967 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. 03/30/192D 3D TSV
US10143704 1 1 Methods for treating cancer Epizyme, Inc. 03/30/192D 3D TSV
USRE47141 78 78 HGNC:11772 Methods of treating fibrosis, cancer and vascular injuries EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION 03/30/192D 3D TSV
US10144731 519 257 HGNC:7782 Nrf2 regulators GlaxoSmithKline Intellectual Property Development Limited; Astex Therapeutics, Ltd 03/30/192D 3D TSV
US10144715 925 407 HGNC:7966 HGNC:7965 Piperazine derivatives as liver X receptor modulators Vitae Pharmaceuticals, Inc. 03/30/192D 3D TSV
US10144738 148 35 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives Pfizer Inc. 03/30/192D 3D TSV
US10138242 229 112 HGNC:8856 Pyrazolopyridine derivatives and their use in therapy TBA 03/30/192D 3D TSV
US10143695 130 26 HGNC:3430 Pyrrolobenzodiazepines and conjugates thereof Mersana Therapeutics, Inc. 03/30/192D 3D TSV
US10144742 520 520 HGNC:30092 Quinoxaline compounds and uses thereof Millennium Pharmaceuticals, Inc. 03/30/192D 3D TSV
US10144734 2116 812 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. 03/30/192D 3D TSV
US10138249 20 20 HGNC:29079 Triazolopyridines and triazolopyrazines as LSD1 inhibitors Incyte Corporation 03/30/192D 3D TSV
US10137110 81 46 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors Bayer Pharma Aktiengesellschaft 03/29/192D 3D TSV
US9597318 7 7 HGNC:9035 2-oxothiazole compounds and method of using same for chronic inflammatory disorders Avexxin AS 03/29/192D 3D TSV
US9598446 65 65 HGNC:2771 Amino compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. 03/29/192D 3D TSV
US10138212 111 111 HGNC:263 Aminoquinazoline compounds as A2A antagonist Merck Sharp & Dohme Corp. 03/29/192D 3D TSV
US9598407 41 41 Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland UC 03/29/192D 3D TSV
US10137202 11 6 HGNC:3590 Antibody-drug conjugates and immunotoxins Oncomatryx Biopharma, S.L. 03/29/192D 3D TSV
US10138230 125 123 HGNC:3357 Autotaxin inhibitors Cancer Research Technology Limited 03/29/192D 3D TSV
US9597333 160 79 HGNC:15631 HGNC:15632 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. 03/29/192D 3D TSV
US10138226 44 35 Benzimidazol-2-amines as MIDH1 inhibitors Bayer Pharma Aktiengesellschaft 03/29/192D 3D TSV
US9597326 26 26 HGNC:15631 Benzonapthyridine compositions and uses thereof GlaxoSmithKline Biologicals SA; U.S. Army Medical Research and Materiel Command 03/29/192D 3D TSV
US10131670 108 36 HGNC:1884 Bicyclic heteroaryl derivatives as CFTR potentiators CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. 03/29/192D 3D TSV
US10131663 194 70 HGNC:6251 HGNC:3467 Chemical compounds AstraZeneca AB 03/29/192D 3D TSV
US9598415 265 261 HGNC:10260 Compounds as modulators of RORγ Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598431 15 4 HGNC:10259 HGNC:10258 HGNC:10260 Compounds useful for inhibiting ROR-gamma-t Eli Lilly and Company 03/29/192D 3D TSV
US10138240 2 2 Crystal of 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative Daiichi Sankyo Company, Limited 03/29/192D 3D TSV
US9597330 60 48 HGNC:10597 Drugs for treating respiratory diseases Daiichi Sankyo Company, Limited 03/29/192D 3D TSV
US10138236 66 33 HGNC:6371 HGNC:3529 Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 03/29/192D 3D TSV
US10138229 156 149 HGNC:1133 Heteroaromatic compounds as BTK inhibitors Boehringer Ingelheim International GmbH 03/29/192D 3D TSV
US9598421 372 103 HGNC:8780 HGNC:8781 HGNC:8783